Pendahuluan
Halaman ini memberikan analisis komprehensif tentang sejarah perdagangan orang dalam yang diketahui dari James C Blair. Orang dalam adalah pejabat, direktur, atau investor signifikan dalam suatu perusahaan. Adalah ilegal bagi orang dalam untuk melakukan perdagangan di perusahaan mereka berdasarkan informasi spesifik yang tidak dipublikasikan. Ini tidak berarti bahwa mereka dilarang melakukan perdagangan apa pun di perusahaan mereka sendiri. Namun, mereka harus melaporkan semua perdagangan kepada SEC melalui Formulir 4. Terlepas dari pembatasan ini, penelitian akademis menunjukkan bahwa orang dalam - secara umum - cenderung mengungguli pasar di perusahaan mereka sendiri.
Rata-rata Profitabilitas Perdagangan
Profitabilitas perdagangan rata-rata adalah pengembalian rata-rata dari semua pembelian pasar terbuka yang dilakukan oleh orang dalam dalam tiga tahun terakhir. Untuk menghitung ini, kami memeriksa setiap pembelian pasar terbuka yang tidak direncanakan yang dilakukan oleh orang dalam, tidak termasuk semua perdagangan yang ditandai sebagai bagian dari rencana perdagangan 10b5-1. Kami kemudian menghitung kinerja rata-rata dari perdagangan tersebut selama 3, 6, dan 12 bulan, dengan merata-ratakan setiap durasi tersebut untuk menghasilkan metrik kinerja akhir untuk setiap perdagangan. Terakhir, kami merata-ratakan semua metrik kinerja untuk menghitung metrik kinerja untuk orang dalam. Daftar ini hanya mencakup orang dalam yang telah melakukan setidaknya tiga perdagangan dalam dua tahun terakhir.
Jika profitabilitas perdagangan orang dalam ini adalah "N/A", maka orang dalam tersebut belum melakukan pembelian di pasar terbuka dalam tiga tahun terakhir, atau perdagangan yang mereka lakukan terlalu baru untuk menghitung metrik kinerja yang andal.
Frekuensi Pembaruan: Setiap Hari
Lihat daftar pedagang dalam perusahaan yang paling menguntungkan.
Perusahaan dengan Posisi Orang Dalam yang Dilaporkan
Pengajuan SEC menunjukkan bahwa James C Blair telah melaporkan kepemilikan atau perdagangan di perusahaan-perusahaan berikut:
Cara Membaca Grafik
Grafik berikut menunjukkan kinerja saham sekuritas setelah setiap perdagangan pasar terbuka yang tidak direncanakan yang dilakukan oleh James C Blair. Perdagangan yang tidak direncanakan adalah perdagangan yang tidak dilakukan sebagai bagian dari rencana perdagangan 10b5-1. Kinerja saham digambarkan sebagai perubahan persentase kumulatif dalam harga saham. Misalnya, jika perdagangan orang dalam dilakukan pada 1 Januari 2019, grafik akan menunjukkan perubahan persentase harian sekuritas hingga saat ini. Jika harga saham naik dari $10 menjadi $15 selama periode ini, perubahan persentase kumulatif dalam harga saham akan menjadi 50%. Perubahan harga dari $10 menjadi $20 akan menjadi 100%, dan perubahan harga dari $10 menjadi $5 akan menjadi -50%.
Pada akhirnya, kita mencoba menentukan seberapa erat korelasi perdagangan orang dalam dengan pengembalian berlebih (positif atau negatif) pada harga saham untuk melihat apakah orang dalam tersebut mengatur waktu perdagangannya untuk mendapatkan keuntungan dari informasi orang dalam. Pertimbangkan situasi di mana orang dalam melakukan hal ini. Dalam situasi ini, kita akan mengharapkan (a) pengembalian positif setelah pembelian, atau (b) pengembalian negatif setelah penjualan. Dalam kasus (a), grafik PEMBELIAN akan menunjukkan serangkaian kurva yang miring ke atas, menunjukkan pengembalian positif setelah setiap transaksi pembelian. Dalam kasus (b), grafik PENJUALAN akan menunjukkan serangkaian kurva yang miring ke bawah, menunjukkan pengembalian negatif setelah setiap transaksi penjualan.
Namun, ini saja tidak cukup untuk menarik kesimpulan. Jika, misalnya, harga saham perusahaan berada dalam tren kenaikan non-siklikal selama bertahun-tahun, maka kita akan mengharapkan semua plot pasca-pembelian memiliki kemiringan ke atas. Demikian pula, penurunan non-siklikal selama bertahun-tahun akan menghasilkan plot pasca-perdagangan dengan kemiringan ke bawah. Tak satu pun dari grafik ini akan menunjukkan aktivitas perdagangan orang dalam.
Indikator terkuat adalah situasi di mana harga saham sangat siklikal, dan terdapat sinyal positif pada grafik PEMBELIAN dan plot negatif pada grafik PENJUALAN. Situasi ini akan sangat menunjukkan adanya orang dalam yang mengatur waktu perdagangan untuk keuntungan finansial mereka.
Pembelian Orang Dalam ADYX / Adynxx, Inc. - Analisis Keuntungan Jangka Pendek
Pada bagian ini, kami menganalisis profitabilitas setiap pembelian saham oleh orang dalam di pasar terbuka yang tidak direncanakan yang dilakukan di ADYX / Adynxx, Inc.. Analisis ini membantu memahami apakah orang dalam tersebut secara konsisten menghasilkan pengembalian abnormal, dan layak untuk diikuti. Analisis ini dilakukan selama satu tahun setelah setiap transaksi, dan hasilnya bersifat teoritis .
Tabel berikut menunjukkan pembelian pasar terbuka terbaru yang bukan bagian dari rencana perdagangan otomatis.
Tanggal Perdagangan | Ticker | Orang Dalam | Dilaporkan Saham |
Dilaporkan Harga |
Disesuaikan Saham |
Disesuaikan Harga |
Dasar Biaya | Hari-hari menuju Maksimal |
Harga di Maksimal |
Maksimal Keuntungan ($) |
Maksimum Pengembalian (%) |
---|---|---|---|---|---|---|---|
Tidak ada transaksi pasar terbuka tak terduga yang diketahui untuk kombinasi orang dalam dan sekuritas ini. |
Harga yang Disesuaikan adalah harga yang disesuaikan dengan pemisahan saham. Saham yang Disesuaikan adalah saham yang disesuaikan dengan pemisahan saham.
Penjualan Orang Dalam ADYX / Adynxx, Inc. - Analisis Kerugian Jangka Pendek
Pada bagian ini, kami menganalisis penghindaran kerugian jangka pendek dari setiap penjualan internal pasar terbuka yang tidak direncanakan yang dilakukan di ADYX / Adynxx, Inc.. Pola penghindaran kerugian yang konsisten dapat menunjukkan bahwa transaksi penjualan di masa mendatang dapat memprediksi penurunan harga. Analisis ini berlaku untuk satu tahun setelah setiap perdagangan, dan hasilnya bersifat teoritis .
Tabel berikut menunjukkan penjualan pasar terbuka terbaru yang bukan bagian dari rencana perdagangan otomatis.
Tanggal Perdagangan | Ticker | Orang Dalam | Dilaporkan Saham |
Dilaporkan Harga |
Disesuaikan Saham |
Disesuaikan Harga |
Dasar Biaya | Hari-hari menuju Menit |
Harga di Menit |
Kerugian Maksimal Dihindari ($) |
Kerugian Maksimal Dihindari (%) |
---|---|---|---|---|---|---|---|
Tidak ada transaksi pasar terbuka tak terduga yang diketahui untuk kombinasi orang dalam dan sekuritas ini. |
Harga yang Disesuaikan adalah harga yang disesuaikan dengan pemisahan saham. Saham yang Disesuaikan adalah saham yang disesuaikan dengan pemisahan saham.
Pembelian Orang Dalam ALDX / Aldeyra Therapeutics, Inc. - Analisis Keuntungan Jangka Pendek
Pada bagian ini, kami menganalisis profitabilitas setiap pembelian saham oleh orang dalam di pasar terbuka yang tidak direncanakan yang dilakukan di ADYX / Adynxx, Inc.. Analisis ini membantu memahami apakah orang dalam tersebut secara konsisten menghasilkan pengembalian abnormal, dan layak untuk diikuti. Analisis ini dilakukan selama satu tahun setelah setiap transaksi, dan hasilnya bersifat teoritis .
Tabel berikut menunjukkan pembelian pasar terbuka terbaru yang bukan bagian dari rencana perdagangan otomatis.
Tanggal Perdagangan | Ticker | Orang Dalam | Dilaporkan Saham |
Dilaporkan Harga |
Disesuaikan Saham |
Disesuaikan Harga |
Dasar Biaya | Hari-hari menuju Maksimal |
Harga di Maksimal |
Maksimal Keuntungan ($) |
Maksimum Pengembalian (%) |
---|---|---|---|---|---|---|---|
Tidak ada transaksi pasar terbuka tak terduga yang diketahui untuk kombinasi orang dalam dan sekuritas ini. |
Harga yang Disesuaikan adalah harga yang disesuaikan dengan pemisahan saham. Saham yang Disesuaikan adalah saham yang disesuaikan dengan pemisahan saham.
Penjualan Orang Dalam ALDX / Aldeyra Therapeutics, Inc. - Analisis Kerugian Jangka Pendek
Pada bagian ini, kami menganalisis penghindaran kerugian jangka pendek dari setiap penjualan internal pasar terbuka yang tidak direncanakan yang dilakukan di ADYX / Adynxx, Inc.. Pola penghindaran kerugian yang konsisten dapat menunjukkan bahwa transaksi penjualan di masa mendatang dapat memprediksi penurunan harga. Analisis ini berlaku untuk satu tahun setelah setiap perdagangan, dan hasilnya bersifat teoritis .
Tabel berikut menunjukkan penjualan pasar terbuka terbaru yang bukan bagian dari rencana perdagangan otomatis.
Tanggal Perdagangan | Ticker | Orang Dalam | Dilaporkan Saham |
Dilaporkan Harga |
Disesuaikan Saham |
Disesuaikan Harga |
Dasar Biaya | Hari-hari menuju Menit |
Harga di Menit |
Kerugian Maksimal Dihindari ($) |
Kerugian Maksimal Dihindari (%) |
---|---|---|---|---|---|---|---|
Tidak ada transaksi pasar terbuka tak terduga yang diketahui untuk kombinasi orang dalam dan sekuritas ini. |
Harga yang Disesuaikan adalah harga yang disesuaikan dengan pemisahan saham. Saham yang Disesuaikan adalah saham yang disesuaikan dengan pemisahan saham.
Pembelian Orang Dalam ATRA / Atara Biotherapeutics, Inc. - Analisis Keuntungan Jangka Pendek
Pada bagian ini, kami menganalisis profitabilitas setiap pembelian saham oleh orang dalam di pasar terbuka yang tidak direncanakan yang dilakukan di ADYX / Adynxx, Inc.. Analisis ini membantu memahami apakah orang dalam tersebut secara konsisten menghasilkan pengembalian abnormal, dan layak untuk diikuti. Analisis ini dilakukan selama satu tahun setelah setiap transaksi, dan hasilnya bersifat teoritis .
Tabel berikut menunjukkan pembelian pasar terbuka terbaru yang bukan bagian dari rencana perdagangan otomatis.
Harga yang Disesuaikan adalah harga yang disesuaikan dengan pemisahan saham. Saham yang Disesuaikan adalah saham yang disesuaikan dengan pemisahan saham.
Penjualan Orang Dalam ATRA / Atara Biotherapeutics, Inc. - Analisis Kerugian Jangka Pendek
Pada bagian ini, kami menganalisis penghindaran kerugian jangka pendek dari setiap penjualan internal pasar terbuka yang tidak direncanakan yang dilakukan di ADYX / Adynxx, Inc.. Pola penghindaran kerugian yang konsisten dapat menunjukkan bahwa transaksi penjualan di masa mendatang dapat memprediksi penurunan harga. Analisis ini berlaku untuk satu tahun setelah setiap perdagangan, dan hasilnya bersifat teoritis .
Tabel berikut menunjukkan penjualan pasar terbuka terbaru yang bukan bagian dari rencana perdagangan otomatis.
Tanggal Perdagangan | Ticker | Orang Dalam | Dilaporkan Saham |
Dilaporkan Harga |
Disesuaikan Saham |
Disesuaikan Harga |
Dasar Biaya | Hari-hari menuju Menit |
Harga di Menit |
Kerugian Maksimal Dihindari ($) |
Kerugian Maksimal Dihindari (%) |
---|---|---|---|---|---|---|---|
Tidak ada transaksi pasar terbuka tak terduga yang diketahui untuk kombinasi orang dalam dan sekuritas ini. |
Harga yang Disesuaikan adalah harga yang disesuaikan dengan pemisahan saham. Saham yang Disesuaikan adalah saham yang disesuaikan dengan pemisahan saham.
Pembelian Orang Dalam ATYR / aTyr Pharma, Inc. - Analisis Keuntungan Jangka Pendek
Pada bagian ini, kami menganalisis profitabilitas setiap pembelian saham oleh orang dalam di pasar terbuka yang tidak direncanakan yang dilakukan di ADYX / Adynxx, Inc.. Analisis ini membantu memahami apakah orang dalam tersebut secara konsisten menghasilkan pengembalian abnormal, dan layak untuk diikuti. Analisis ini dilakukan selama satu tahun setelah setiap transaksi, dan hasilnya bersifat teoritis .
Tabel berikut menunjukkan pembelian pasar terbuka terbaru yang bukan bagian dari rencana perdagangan otomatis.
Tanggal Perdagangan | Ticker | Orang Dalam | Dilaporkan Saham |
Dilaporkan Harga |
Disesuaikan Saham |
Disesuaikan Harga |
Dasar Biaya | Hari-hari menuju Maksimal |
Harga di Maksimal |
Maksimal Keuntungan ($) |
Maksimum Pengembalian (%) |
---|---|---|---|---|---|---|---|
Tidak ada transaksi pasar terbuka tak terduga yang diketahui untuk kombinasi orang dalam dan sekuritas ini. |
Harga yang Disesuaikan adalah harga yang disesuaikan dengan pemisahan saham. Saham yang Disesuaikan adalah saham yang disesuaikan dengan pemisahan saham.
Penjualan Orang Dalam ATYR / aTyr Pharma, Inc. - Analisis Kerugian Jangka Pendek
Pada bagian ini, kami menganalisis penghindaran kerugian jangka pendek dari setiap penjualan internal pasar terbuka yang tidak direncanakan yang dilakukan di ADYX / Adynxx, Inc.. Pola penghindaran kerugian yang konsisten dapat menunjukkan bahwa transaksi penjualan di masa mendatang dapat memprediksi penurunan harga. Analisis ini berlaku untuk satu tahun setelah setiap perdagangan, dan hasilnya bersifat teoritis .
Tabel berikut menunjukkan penjualan pasar terbuka terbaru yang bukan bagian dari rencana perdagangan otomatis.
Tanggal Perdagangan | Ticker | Orang Dalam | Dilaporkan Saham |
Dilaporkan Harga |
Disesuaikan Saham |
Disesuaikan Harga |
Dasar Biaya | Hari-hari menuju Menit |
Harga di Menit |
Kerugian Maksimal Dihindari ($) |
Kerugian Maksimal Dihindari (%) |
---|---|---|---|---|---|---|---|
Tidak ada transaksi pasar terbuka tak terduga yang diketahui untuk kombinasi orang dalam dan sekuritas ini. |
Harga yang Disesuaikan adalah harga yang disesuaikan dengan pemisahan saham. Saham yang Disesuaikan adalah saham yang disesuaikan dengan pemisahan saham.
Pembelian Orang Dalam BNGO / Bionano Genomics, Inc. - Analisis Keuntungan Jangka Pendek
Pada bagian ini, kami menganalisis profitabilitas setiap pembelian saham oleh orang dalam di pasar terbuka yang tidak direncanakan yang dilakukan di ADYX / Adynxx, Inc.. Analisis ini membantu memahami apakah orang dalam tersebut secara konsisten menghasilkan pengembalian abnormal, dan layak untuk diikuti. Analisis ini dilakukan selama satu tahun setelah setiap transaksi, dan hasilnya bersifat teoritis .
Tabel berikut menunjukkan pembelian pasar terbuka terbaru yang bukan bagian dari rencana perdagangan otomatis.
Tanggal Perdagangan | Ticker | Orang Dalam | Dilaporkan Saham |
Dilaporkan Harga |
Disesuaikan Saham |
Disesuaikan Harga |
Dasar Biaya | Hari-hari menuju Maksimal |
Harga di Maksimal |
Maksimal Keuntungan ($) |
Maksimum Pengembalian (%) |
---|---|---|---|---|---|---|---|---|---|---|---|
2018-08-23 | BNGO | Domain Partners VIII, L.P. | 15,000 | 6.1250 | 429 | 214.3750 | 91,875 | 35 | 82.5 | -56,565 | -61.57 |
Harga yang Disesuaikan adalah harga yang disesuaikan dengan pemisahan saham. Saham yang Disesuaikan adalah saham yang disesuaikan dengan pemisahan saham.
Penjualan Orang Dalam BNGO / Bionano Genomics, Inc. - Analisis Kerugian Jangka Pendek
Pada bagian ini, kami menganalisis penghindaran kerugian jangka pendek dari setiap penjualan internal pasar terbuka yang tidak direncanakan yang dilakukan di ADYX / Adynxx, Inc.. Pola penghindaran kerugian yang konsisten dapat menunjukkan bahwa transaksi penjualan di masa mendatang dapat memprediksi penurunan harga. Analisis ini berlaku untuk satu tahun setelah setiap perdagangan, dan hasilnya bersifat teoritis .
Tabel berikut menunjukkan penjualan pasar terbuka terbaru yang bukan bagian dari rencana perdagangan otomatis.
Tanggal Perdagangan | Ticker | Orang Dalam | Dilaporkan Saham |
Dilaporkan Harga |
Disesuaikan Saham |
Disesuaikan Harga |
Dasar Biaya | Hari-hari menuju Menit |
Harga di Menit |
Kerugian Maksimal Dihindari ($) |
Kerugian Maksimal Dihindari (%) |
---|---|---|---|---|---|---|---|
Tidak ada transaksi pasar terbuka tak terduga yang diketahui untuk kombinasi orang dalam dan sekuritas ini. |
Harga yang Disesuaikan adalah harga yang disesuaikan dengan pemisahan saham. Saham yang Disesuaikan adalah saham yang disesuaikan dengan pemisahan saham.
Pembelian Orang Dalam ESPR / Esperion Therapeutics, Inc. - Analisis Keuntungan Jangka Pendek
Pada bagian ini, kami menganalisis profitabilitas setiap pembelian saham oleh orang dalam di pasar terbuka yang tidak direncanakan yang dilakukan di ADYX / Adynxx, Inc.. Analisis ini membantu memahami apakah orang dalam tersebut secara konsisten menghasilkan pengembalian abnormal, dan layak untuk diikuti. Analisis ini dilakukan selama satu tahun setelah setiap transaksi, dan hasilnya bersifat teoritis .
Tabel berikut menunjukkan pembelian pasar terbuka terbaru yang bukan bagian dari rencana perdagangan otomatis.
Tanggal Perdagangan | Ticker | Orang Dalam | Dilaporkan Saham |
Dilaporkan Harga |
Disesuaikan Saham |
Disesuaikan Harga |
Dasar Biaya | Hari-hari menuju Maksimal |
Harga di Maksimal |
Maksimal Keuntungan ($) |
Maksimum Pengembalian (%) |
---|---|---|---|---|---|---|---|---|---|---|---|
2014-10-21 | ESPR | DOMAIN PARTERS VII L P | 500,000 | 20.0000 | 500,000 | 20.0000 | 10,000,000 | 210 | 115.3000 | 47,650,000 | 476.50 |
Harga yang Disesuaikan adalah harga yang disesuaikan dengan pemisahan saham. Saham yang Disesuaikan adalah saham yang disesuaikan dengan pemisahan saham.
Penjualan Orang Dalam ESPR / Esperion Therapeutics, Inc. - Analisis Kerugian Jangka Pendek
Pada bagian ini, kami menganalisis penghindaran kerugian jangka pendek dari setiap penjualan internal pasar terbuka yang tidak direncanakan yang dilakukan di ADYX / Adynxx, Inc.. Pola penghindaran kerugian yang konsisten dapat menunjukkan bahwa transaksi penjualan di masa mendatang dapat memprediksi penurunan harga. Analisis ini berlaku untuk satu tahun setelah setiap perdagangan, dan hasilnya bersifat teoritis .
Tabel berikut menunjukkan penjualan pasar terbuka terbaru yang bukan bagian dari rencana perdagangan otomatis.
Tanggal Perdagangan | Ticker | Orang Dalam | Dilaporkan Saham |
Dilaporkan Harga |
Disesuaikan Saham |
Disesuaikan Harga |
Dasar Biaya | Hari-hari menuju Menit |
Harga di Menit |
Kerugian Maksimal Dihindari ($) |
Kerugian Maksimal Dihindari (%) |
---|---|---|---|---|---|---|---|
Tidak ada transaksi pasar terbuka tak terduga yang diketahui untuk kombinasi orang dalam dan sekuritas ini. |
Harga yang Disesuaikan adalah harga yang disesuaikan dengan pemisahan saham. Saham yang Disesuaikan adalah saham yang disesuaikan dengan pemisahan saham.
Pembelian Orang Dalam EVOK / Evoke Pharma, Inc. - Analisis Keuntungan Jangka Pendek
Pada bagian ini, kami menganalisis profitabilitas setiap pembelian saham oleh orang dalam di pasar terbuka yang tidak direncanakan yang dilakukan di ADYX / Adynxx, Inc.. Analisis ini membantu memahami apakah orang dalam tersebut secara konsisten menghasilkan pengembalian abnormal, dan layak untuk diikuti. Analisis ini dilakukan selama satu tahun setelah setiap transaksi, dan hasilnya bersifat teoritis .
Tabel berikut menunjukkan pembelian pasar terbuka terbaru yang bukan bagian dari rencana perdagangan otomatis.
Tanggal Perdagangan | Ticker | Orang Dalam | Dilaporkan Saham |
Dilaporkan Harga |
Disesuaikan Saham |
Disesuaikan Harga |
Dasar Biaya | Hari-hari menuju Maksimal |
Harga di Maksimal |
Maksimal Keuntungan ($) |
Maksimum Pengembalian (%) |
---|---|---|---|---|---|---|---|
Tidak ada transaksi pasar terbuka tak terduga yang diketahui untuk kombinasi orang dalam dan sekuritas ini. |
Harga yang Disesuaikan adalah harga yang disesuaikan dengan pemisahan saham. Saham yang Disesuaikan adalah saham yang disesuaikan dengan pemisahan saham.
Penjualan Orang Dalam EVOK / Evoke Pharma, Inc. - Analisis Kerugian Jangka Pendek
Pada bagian ini, kami menganalisis penghindaran kerugian jangka pendek dari setiap penjualan internal pasar terbuka yang tidak direncanakan yang dilakukan di ADYX / Adynxx, Inc.. Pola penghindaran kerugian yang konsisten dapat menunjukkan bahwa transaksi penjualan di masa mendatang dapat memprediksi penurunan harga. Analisis ini berlaku untuk satu tahun setelah setiap perdagangan, dan hasilnya bersifat teoritis .
Tabel berikut menunjukkan penjualan pasar terbuka terbaru yang bukan bagian dari rencana perdagangan otomatis.
Harga yang Disesuaikan adalah harga yang disesuaikan dengan pemisahan saham. Saham yang Disesuaikan adalah saham yang disesuaikan dengan pemisahan saham.
Pembelian Orang Dalam GKOS / Glaukos Corporation - Analisis Keuntungan Jangka Pendek
Pada bagian ini, kami menganalisis profitabilitas setiap pembelian saham oleh orang dalam di pasar terbuka yang tidak direncanakan yang dilakukan di ADYX / Adynxx, Inc.. Analisis ini membantu memahami apakah orang dalam tersebut secara konsisten menghasilkan pengembalian abnormal, dan layak untuk diikuti. Analisis ini dilakukan selama satu tahun setelah setiap transaksi, dan hasilnya bersifat teoritis .
Tabel berikut menunjukkan pembelian pasar terbuka terbaru yang bukan bagian dari rencana perdagangan otomatis.
Tanggal Perdagangan | Ticker | Orang Dalam | Dilaporkan Saham |
Dilaporkan Harga |
Disesuaikan Saham |
Disesuaikan Harga |
Dasar Biaya | Hari-hari menuju Maksimal |
Harga di Maksimal |
Maksimal Keuntungan ($) |
Maksimum Pengembalian (%) |
---|---|---|---|---|---|---|---|
Tidak ada transaksi pasar terbuka tak terduga yang diketahui untuk kombinasi orang dalam dan sekuritas ini. |
Harga yang Disesuaikan adalah harga yang disesuaikan dengan pemisahan saham. Saham yang Disesuaikan adalah saham yang disesuaikan dengan pemisahan saham.
Penjualan Orang Dalam GKOS / Glaukos Corporation - Analisis Kerugian Jangka Pendek
Pada bagian ini, kami menganalisis penghindaran kerugian jangka pendek dari setiap penjualan internal pasar terbuka yang tidak direncanakan yang dilakukan di ADYX / Adynxx, Inc.. Pola penghindaran kerugian yang konsisten dapat menunjukkan bahwa transaksi penjualan di masa mendatang dapat memprediksi penurunan harga. Analisis ini berlaku untuk satu tahun setelah setiap perdagangan, dan hasilnya bersifat teoritis .
Tabel berikut menunjukkan penjualan pasar terbuka terbaru yang bukan bagian dari rencana perdagangan otomatis.
Tanggal Perdagangan | Ticker | Orang Dalam | Dilaporkan Saham |
Dilaporkan Harga |
Disesuaikan Saham |
Disesuaikan Harga |
Dasar Biaya | Hari-hari menuju Menit |
Harga di Menit |
Kerugian Maksimal Dihindari ($) |
Kerugian Maksimal Dihindari (%) |
---|---|---|---|---|---|---|---|
Tidak ada transaksi pasar terbuka tak terduga yang diketahui untuk kombinasi orang dalam dan sekuritas ini. |
Harga yang Disesuaikan adalah harga yang disesuaikan dengan pemisahan saham. Saham yang Disesuaikan adalah saham yang disesuaikan dengan pemisahan saham.
Pembelian Orang Dalam SNDX / Syndax Pharmaceuticals, Inc. - Analisis Keuntungan Jangka Pendek
Pada bagian ini, kami menganalisis profitabilitas setiap pembelian saham oleh orang dalam di pasar terbuka yang tidak direncanakan yang dilakukan di ADYX / Adynxx, Inc.. Analisis ini membantu memahami apakah orang dalam tersebut secara konsisten menghasilkan pengembalian abnormal, dan layak untuk diikuti. Analisis ini dilakukan selama satu tahun setelah setiap transaksi, dan hasilnya bersifat teoritis .
Tabel berikut menunjukkan pembelian pasar terbuka terbaru yang bukan bagian dari rencana perdagangan otomatis.
Tanggal Perdagangan | Ticker | Orang Dalam | Dilaporkan Saham |
Dilaporkan Harga |
Disesuaikan Saham |
Disesuaikan Harga |
Dasar Biaya | Hari-hari menuju Maksimal |
Harga di Maksimal |
Maksimal Keuntungan ($) |
Maksimum Pengembalian (%) |
---|---|---|---|---|---|---|---|
Tidak ada transaksi pasar terbuka tak terduga yang diketahui untuk kombinasi orang dalam dan sekuritas ini. |
Harga yang Disesuaikan adalah harga yang disesuaikan dengan pemisahan saham. Saham yang Disesuaikan adalah saham yang disesuaikan dengan pemisahan saham.
Penjualan Orang Dalam SNDX / Syndax Pharmaceuticals, Inc. - Analisis Kerugian Jangka Pendek
Pada bagian ini, kami menganalisis penghindaran kerugian jangka pendek dari setiap penjualan internal pasar terbuka yang tidak direncanakan yang dilakukan di ADYX / Adynxx, Inc.. Pola penghindaran kerugian yang konsisten dapat menunjukkan bahwa transaksi penjualan di masa mendatang dapat memprediksi penurunan harga. Analisis ini berlaku untuk satu tahun setelah setiap perdagangan, dan hasilnya bersifat teoritis .
Tabel berikut menunjukkan penjualan pasar terbuka terbaru yang bukan bagian dari rencana perdagangan otomatis.
Tanggal Perdagangan | Ticker | Orang Dalam | Dilaporkan Saham |
Dilaporkan Harga |
Disesuaikan Saham |
Disesuaikan Harga |
Dasar Biaya | Hari-hari menuju Menit |
Harga di Menit |
Kerugian Maksimal Dihindari ($) |
Kerugian Maksimal Dihindari (%) |
---|---|---|---|---|---|---|---|
Tidak ada transaksi pasar terbuka tak terduga yang diketahui untuk kombinasi orang dalam dan sekuritas ini. |
Harga yang Disesuaikan adalah harga yang disesuaikan dengan pemisahan saham. Saham yang Disesuaikan adalah saham yang disesuaikan dengan pemisahan saham.
Pembelian Orang Dalam VCYT / Veracyte, Inc. - Analisis Keuntungan Jangka Pendek
Pada bagian ini, kami menganalisis profitabilitas setiap pembelian saham oleh orang dalam di pasar terbuka yang tidak direncanakan yang dilakukan di ADYX / Adynxx, Inc.. Analisis ini membantu memahami apakah orang dalam tersebut secara konsisten menghasilkan pengembalian abnormal, dan layak untuk diikuti. Analisis ini dilakukan selama satu tahun setelah setiap transaksi, dan hasilnya bersifat teoritis .
Tabel berikut menunjukkan pembelian pasar terbuka terbaru yang bukan bagian dari rencana perdagangan otomatis.
Tanggal Perdagangan | Ticker | Orang Dalam | Dilaporkan Saham |
Dilaporkan Harga |
Disesuaikan Saham |
Disesuaikan Harga |
Dasar Biaya | Hari-hari menuju Maksimal |
Harga di Maksimal |
Maksimal Keuntungan ($) |
Maksimum Pengembalian (%) |
---|---|---|---|---|---|---|---|
Tidak ada transaksi pasar terbuka tak terduga yang diketahui untuk kombinasi orang dalam dan sekuritas ini. |
Harga yang Disesuaikan adalah harga yang disesuaikan dengan pemisahan saham. Saham yang Disesuaikan adalah saham yang disesuaikan dengan pemisahan saham.
Penjualan Orang Dalam VCYT / Veracyte, Inc. - Analisis Kerugian Jangka Pendek
Pada bagian ini, kami menganalisis penghindaran kerugian jangka pendek dari setiap penjualan internal pasar terbuka yang tidak direncanakan yang dilakukan di ADYX / Adynxx, Inc.. Pola penghindaran kerugian yang konsisten dapat menunjukkan bahwa transaksi penjualan di masa mendatang dapat memprediksi penurunan harga. Analisis ini berlaku untuk satu tahun setelah setiap perdagangan, dan hasilnya bersifat teoritis .
Tabel berikut menunjukkan penjualan pasar terbuka terbaru yang bukan bagian dari rencana perdagangan otomatis.
Tanggal Perdagangan | Ticker | Orang Dalam | Dilaporkan Saham |
Dilaporkan Harga |
Disesuaikan Saham |
Disesuaikan Harga |
Dasar Biaya | Hari-hari menuju Menit |
Harga di Menit |
Kerugian Maksimal Dihindari ($) |
Kerugian Maksimal Dihindari (%) |
---|---|---|---|---|---|---|---|
Tidak ada transaksi pasar terbuka tak terduga yang diketahui untuk kombinasi orang dalam dan sekuritas ini. |
Harga yang Disesuaikan adalah harga yang disesuaikan dengan pemisahan saham. Saham yang Disesuaikan adalah saham yang disesuaikan dengan pemisahan saham.
Sejarah Perdagangan Orang Dalam
Tabel ini menunjukkan daftar lengkap transaksi orang dalam yang dilakukan oleh James C Blair sebagaimana diungkapkan kepada Komisi Bursa Efek (Securities Exchange Commission/SEC).
Tanggal File | Tanggal Transaksi | Formulir | Ticker | Keamanan | Kode | Saham | Sisa Saham | Persen Ubah |
Bagikan Harga |
Tran Nilai |
Sisa Nilai |
|
---|---|---|---|---|---|---|---|---|---|---|---|---|
2021-06-11 |
|
4 | CLVS |
Clovis Oncology, Inc.
Stock Option (right to buy) |
A - Award | 42,223 | 42,223 | |||||
2020-06-05 |
|
4 | CLVS |
Clovis Oncology, Inc.
Stock Option (right to buy) |
A - Award | 40,138 | 40,138 | |||||
2019-08-20 |
|
4 | CLVS |
Clovis Oncology, Inc.
Common Stock |
P - Purchase | 20,000 | 20,000 | 5.97 | 119,400 | 119,400 | ||
2019-08-20 |
|
4 | CLVS |
Clovis Oncology, Inc.
Common Stock |
P - Purchase | 20,000 | 33,439 | 148.82 | 5.70 | 114,000 | 190,602 | |
2019-08-08 |
|
4 | OBLN |
OBALON THERAPEUTICS INC
Warrants to Purchase Common Stock |
P - Purchase | 187,500 | 187,500 | 4.00 | 750,000 | 750,000 | ||
2019-08-08 |
|
4 | OBLN |
OBALON THERAPEUTICS INC
Common Stock |
P - Purchase | 250,000 | 813,433 | 44.37 | 4.00 | 1,000,000 | 3,253,732 | |
2019-06-10 |
|
4 | CLVS |
Clovis Oncology, Inc.
Stock Option (Right to buy) |
A - Award | 28,882 | 28,882 | |||||
2019-05-13 | 3 | ADYX |
Alliqua BioMedical, Inc.
Common Stock |
45,054 | ||||||||
2019-05-13 | 3 | ADYX |
Alliqua BioMedical, Inc.
Common Stock |
45,054 | ||||||||
2019-05-13 | 3 | ADYX |
Alliqua BioMedical, Inc.
Common Stock |
45,054 | ||||||||
2019-05-13 | 3 | ADYX |
Alliqua BioMedical, Inc.
Common Stock |
45,054 | ||||||||
2019-05-13 | 3 | ADYX |
Alliqua BioMedical, Inc.
Common Stock |
45,054 | ||||||||
2019-05-13 | 3 | ADYX |
Alliqua BioMedical, Inc.
Common Stock |
45,054 | ||||||||
2019-05-13 | 3 | ADYX |
Alliqua BioMedical, Inc.
Common Stock |
45,054 | ||||||||
2019-05-13 | 3 | ADYX |
Alliqua BioMedical, Inc.
Common Stock |
45,054 | ||||||||
2019-05-13 | 3 | ADYX |
Alliqua BioMedical, Inc.
Common Stock |
6,072,088 | ||||||||
2019-05-13 | 3 | ADYX |
Alliqua BioMedical, Inc.
Common Stock |
6,072,088 | ||||||||
2019-05-13 | 3 | ADYX |
Alliqua BioMedical, Inc.
Common Stock |
6,072,088 | ||||||||
2019-05-13 | 3 | ADYX |
Alliqua BioMedical, Inc.
Common Stock |
6,072,088 | ||||||||
2019-05-13 | 3 | ADYX |
Alliqua BioMedical, Inc.
Common Stock |
6,072,088 | ||||||||
2019-05-13 | 3 | ADYX |
Alliqua BioMedical, Inc.
Common Stock |
6,072,088 | ||||||||
2019-05-13 | 3 | ADYX |
Alliqua BioMedical, Inc.
Common Stock |
6,072,088 | ||||||||
2019-05-13 | 3 | ADYX |
Alliqua BioMedical, Inc.
Common Stock |
6,072,088 | ||||||||
2019-05-10 |
|
4 | LIFE |
aTYR PHARMA INC
Stock Option (right to buy) |
A - Award | 20,000 | 20,000 | |||||
2019-03-18 |
|
4 | CLVS |
Clovis Oncology, Inc.
Common Stock |
J - Other | 522 | 13,439 | 4.04 | ||||
2019-03-18 |
|
4 | CLVS |
Clovis Oncology, Inc.
Common Stock |
J - Other | 701 | 10,105 | 7.45 | ||||
2019-03-18 |
|
4 | CLVS |
Clovis Oncology, Inc.
Common Stock |
J - Other | -10,000 | 0 | -100.00 | ||||
2019-03-18 |
|
4 | CLVS |
Clovis Oncology, Inc.
Common Stock |
S - Sale | -17,056 | 0 | -100.00 | 27.79 | -473,986 | ||
2019-02-05 |
|
4 | CLVS |
Clovis Oncology, Inc.
Common Stock |
J - Other | 10,000 | 10,000 | |||||
2019-02-05 |
|
4 | CLVS |
Clovis Oncology, Inc.
Common Stock |
J - Other | -1,000,000 | 0 | -100.00 | ||||
2018-10-15 |
|
4 | CLVS |
Clovis Oncology, Inc.
Stock Option (Right to buy) |
A - Award | 14,770 | 14,770 | |||||
2018-08-27 |
|
4 | BNGO |
BioNano Genomics, Inc
Warrants to Purchase Common Stock |
P - Purchase | 15,000 | 15,000 | |||||
2018-08-27 |
|
4 | BNGO |
BioNano Genomics, Inc
Series B Preferred Stock |
C - Conversion | -6,810,098 | 0 | -100.00 | ||||
2018-08-27 |
|
4 | BNGO |
BioNano Genomics, Inc
Convertible Promissory Note |
C - Conversion | 0 | ||||||
2018-08-27 |
|
4 | BNGO |
BioNano Genomics, Inc
Series D-1 Preferred Stock |
C - Conversion | -3,682,919 | 0 | -100.00 | ||||
2018-08-27 |
|
4 | BNGO |
BioNano Genomics, Inc
Series D Preferred Stock |
C - Conversion | -6,396,105 | 0 | -100.00 | ||||
2018-08-27 |
|
4 | BNGO |
BioNano Genomics, Inc
Series C Preferred Stock |
C - Conversion | -5,426,808 | 0 | -100.00 | ||||
2018-08-27 |
|
4 | BNGO |
BioNano Genomics, Inc
Series B-1 Preferred Stock |
C - Conversion | -2,986,762 | 0 | -100.00 | ||||
2018-08-27 |
|
4 | BNGO |
BioNano Genomics, Inc
Common Stock |
P - Purchase | 15,000 | 943,878 | 1.61 | 6.12 | 91,875 | 5,781,253 | |
2018-08-27 |
|
4 | BNGO |
BioNano Genomics, Inc
Common Stock |
C - Conversion | 337,694 | 929,878 | 57.03 | 4.59 | 1,550,015 | 4,268,140 | |
2018-08-27 |
|
4 | BNGO |
BioNano Genomics, Inc
Common Stock |
C - Conversion | 591,184 | 591,184 | |||||
2018-08-27 |
|
4 | BNGO |
BioNano Genomics, Inc
Series B Preferred Stock |
C - Conversion | -50,532 | 0 | -100.00 | ||||
2018-08-27 |
|
4 | BNGO |
BioNano Genomics, Inc
Convertible Promissory Note |
C - Conversion | 0 | ||||||
2018-08-27 |
|
4 | BNGO |
BioNano Genomics, Inc
Series D-1 Preferred Stock |
C - Conversion | -27,328 | 0 | -100.00 | ||||
2018-08-27 |
|
4 | BNGO |
BioNano Genomics, Inc
Series D Preferred Stock |
C - Conversion | -47,460 | 0 | -100.00 | ||||
2018-08-27 |
|
4 | BNGO |
BioNano Genomics, Inc
Series C Preferred Stock |
C - Conversion | -40,268 | 0 | -100.00 | ||||
2018-08-27 |
|
4 | BNGO |
BioNano Genomics, Inc
Series B-1 Preferred Stock |
C - Conversion | -22,161 | 0 | -100.00 | ||||
2018-08-27 |
|
4 | BNGO |
BioNano Genomics, Inc
Common Stock |
C - Conversion | 2,505 | 6,891 | 57.11 | 4.59 | 11,498 | 31,630 | |
2018-08-27 |
|
4 | BNGO |
BioNano Genomics, Inc
Common Stock |
C - Conversion | 4,386 | 4,386 | |||||
2018-08-27 |
|
4 | OBLN |
OBALON THERAPEUTICS INC
Common Stock |
P - Purchase | 1,648,359 | 5,634,329 | 41.35 | 1.82 | 3,000,013 | 10,254,479 | |
2018-08-21 | 3 | BNGO |
BioNano Genomics, Inc
Common Stock |
280 | ||||||||
2018-08-21 | 3 | BNGO |
BioNano Genomics, Inc
Common Stock |
280 | ||||||||
2018-08-21 | 3 | BNGO |
BioNano Genomics, Inc
Common Stock |
280 | ||||||||
2018-08-21 | 3 | BNGO |
BioNano Genomics, Inc
Common Stock |
280 | ||||||||
2018-08-21 | 3 | BNGO |
BioNano Genomics, Inc
Common Stock |
280 | ||||||||
2018-08-21 | 3 | BNGO |
BioNano Genomics, Inc
Common Stock |
280 | ||||||||
2018-08-21 | 3 | BNGO |
BioNano Genomics, Inc
Common Stock |
280 | ||||||||
2018-08-21 | 3 | BNGO |
BioNano Genomics, Inc
Common Stock |
280 | ||||||||
2018-05-23 |
|
4 | CLVS |
Clovis Oncology, Inc.
Common Stock |
J - Other | 5,897 | 12,917 | 84.00 | ||||
2018-05-23 |
|
4 | CLVS |
Clovis Oncology, Inc.
Common Stock |
J - Other | -32,760 | 0 | -100.00 | ||||
2018-05-17 |
|
4 | LIFE |
aTYR PHARMA INC
Stock Option (right to buy) |
A - Award | 20,000 | 20,000 | |||||
2017-12-20 |
|
4 | DRNA |
Dicerna Pharmaceuticals Inc
Redeemable Convertible Preferred Stock |
C - Conversion | -368 | 0 | -100.00 | ||||
2017-12-20 |
|
4 | DRNA |
Dicerna Pharmaceuticals Inc
Common Stock |
A - Award | 282 | 25,730 | 1.11 | ||||
2017-12-20 |
|
4 | DRNA |
Dicerna Pharmaceuticals Inc
Common Stock |
C - Conversion | 12,444 | 25,448 | 95.69 | 3.19 | 39,696 | 81,179 | |
2017-12-20 |
|
4 | DRNA |
Dicerna Pharmaceuticals Inc
Redeemable Convertible Preferred Stock |
C - Conversion | -49,632 | 0 | -100.00 | ||||
2017-12-20 |
|
4 | DRNA |
Dicerna Pharmaceuticals Inc
Common Stock |
A - Award | 37,890 | 3,469,029 | 1.10 | ||||
2017-12-20 |
|
4 | DRNA |
Dicerna Pharmaceuticals Inc
Common Stock |
C - Conversion | 1,678,432 | 3,431,139 | 95.76 | 3.19 | 5,354,198 | 10,945,333 | |
2017-12-13 |
|
4 | OCRX |
Ocera Therapeutics, Inc.
Common Stock |
D - Sale to Issuer | -988,285 | 0 | -100.00 | ||||
2017-12-13 |
|
4 | OCRX |
Ocera Therapeutics, Inc.
Common Stock |
D - Sale to Issuer | -47,963 | 0 | -100.00 | ||||
2017-12-13 |
|
4 | OCRX |
Ocera Therapeutics, Inc.
Common Stock |
D - Sale to Issuer | -15,731 | 0 | -100.00 | ||||
2017-12-13 |
|
4 | OCRX |
Ocera Therapeutics, Inc.
Warrant to Purchase Common Stock |
D - Sale to Issuer | -20,150 | 0 | -100.00 | ||||
2017-12-13 |
|
4 | OCRX |
Ocera Therapeutics, Inc.
Warrant to Purchase Common Stock |
D - Sale to Issuer | -20,150 | 0 | -100.00 | ||||
2017-12-13 |
|
4 | OCRX |
Ocera Therapeutics, Inc.
Common Stock |
D - Sale to Issuer | -1,857,036 | 0 | -100.00 | ||||
2017-12-13 |
|
4 | OCRX |
Ocera Therapeutics, Inc.
Common Stock |
D - Sale to Issuer | -7,333 | 0 | -100.00 | ||||
2017-08-18 |
|
4 | CLVS |
Clovis Oncology, Inc.
Common Stock |
J - Other | 6,477 | 9,404 | 221.28 | ||||
2017-08-18 |
|
4 | CLVS |
Clovis Oncology, Inc.
Common Stock |
J - Other | 4,835 | 7,020 | 221.28 | ||||
2017-08-18 |
|
4 | CLVS |
Clovis Oncology, Inc.
Common Stock |
J - Other | -92,518 | 0 | -100.00 | ||||
2017-08-08 |
|
4 | CLVS |
Clovis Oncology, Inc.
Common Stock |
S - Sale | -18,450 | 17,056 | -51.96 | 78.61 | -1,450,354 | 1,340,772 | |
2017-06-27 |
|
4 | CLVS |
Clovis Oncology, Inc.
Common Stock |
J - Other | 2,869 | 92,518 | 3.20 | ||||
2017-06-27 |
|
4 | CLVS |
Clovis Oncology, Inc.
Common Stock |
J - Other | -286,857 | 1,000,000 | -22.29 | ||||
2017-06-12 |
|
4 | CLVS |
Clovis Oncology, Inc.
Stock Option (Right to buy) |
A - Award | 10,000 | 10,000 | |||||
2017-05-23 |
|
4/A | CLVS |
Clovis Oncology, Inc.
Common Stock |
J - Other | 2,927 | 2,927 | |||||
2017-05-23 |
|
4/A | CLVS |
Clovis Oncology, Inc.
Common Stock |
J - Other | 2,185 | 2,185 | |||||
2017-05-23 |
|
4/A | CLVS |
Clovis Oncology, Inc.
Common Stock |
J - Other | -41,813 | 0 | -100.00 | ||||
2017-05-11 |
|
4 | LIFE |
aTYR PHARMA INC
Stock Option (right to buy) |
A - Award | 20,000 | 20,000 | |||||
2017-04-12 |
|
4 | DRNA |
Dicerna Pharmaceuticals Inc
Redeemable Convertible Preferred Stock |
P - Purchase | 49,632 | 49,632 | 100.00 | 4,963,200 | 4,963,200 | ||
2017-04-12 |
|
4 | DRNA |
Dicerna Pharmaceuticals Inc
Redeemable Convertible Preferred Stock |
P - Purchase | 368 | 368 | 100.00 | 36,800 | 36,800 | ||
2016-11-04 |
|
4 | TBRA |
Tobira Therapeutics, Inc.
Stock Option (Right to Buy) |
D - Sale to Issuer | 17,695 | 0 | -100.00 | ||||
2016-11-04 |
|
4 | TBRA |
Tobira Therapeutics, Inc.
Stock Option (Right to Buy) |
D - Sale to Issuer | 1,071 | 0 | -100.00 | ||||
2016-11-04 |
|
4 | TBRA |
Tobira Therapeutics, Inc.
Stock Option (Right to Buy) |
D - Sale to Issuer | 1,996 | 0 | -100.00 | ||||
2016-11-04 |
|
4 | TBRA |
Tobira Therapeutics, Inc.
Common Stock |
U - Other | -38,094 | 0 | -100.00 | 28.35 | -1,079,965 | ||
2016-11-03 |
|
4 | TBRA |
Tobira Therapeutics, Inc.
Common Stock |
U - Other | -3,553,322 | 0 | -100.00 | 28.35 | -100,736,679 | ||
2016-11-03 |
|
4 | TBRA |
Tobira Therapeutics, Inc.
Common Stock |
U - Other | -47,613 | 0 | -100.00 | 28.35 | -1,349,829 | ||
2016-11-03 |
|
4 | TBRA |
Tobira Therapeutics, Inc.
Common Stock |
U - Other | -1,657 | 0 | -100.00 | 28.35 | -46,976 | ||
2016-11-03 |
|
4 | TBRA |
Tobira Therapeutics, Inc.
Common Stock |
U - Other | -285,679 | 0 | -100.00 | 28.35 | -8,099,000 | ||
2016-10-14 |
|
4 | OBLN |
OBALON THERAPEUTICS INC
Series C Preferred Stock |
C - Conversion | -14,271 | 0 | -100.00 | ||||
2016-10-14 |
|
4 | OBLN |
OBALON THERAPEUTICS INC
Series B Preferred Stock |
C - Conversion | -20,583 | 0 | -100.00 | ||||
2016-10-14 |
|
4 | OBLN |
OBALON THERAPEUTICS INC
Series A Preferred Stock |
C - Conversion | -11,083 | 0 | -100.00 | ||||
2016-10-14 |
|
4 | OBLN |
OBALON THERAPEUTICS INC
Common Stock |
C - Conversion | 49,570 | 49,570 | |||||
2016-10-14 |
|
4 | OBLN |
OBALON THERAPEUTICS INC
Series E Preferred Stock |
C - Conversion | -482,326 | 0 | -100.00 | ||||
2016-10-14 |
|
4 | OBLN |
OBALON THERAPEUTICS INC
Series D Preferred Stock |
C - Conversion | -597,207 | 0 | -100.00 | ||||
2016-10-14 |
|
4 | OBLN |
OBALON THERAPEUTICS INC
Series C Preferred Stock |
C - Conversion | -836,722 | 0 | -100.00 | ||||
2016-10-14 |
|
4 | OBLN |
OBALON THERAPEUTICS INC
Series B Preferred Stock |
C - Conversion | -1,206,836 | 0 | -100.00 | ||||
2016-10-14 |
|
4 | OBLN |
OBALON THERAPEUTICS INC
Series A Preferred Stock |
C - Conversion | -649,835 | 0 | -100.00 | ||||
2016-10-14 |
|
4 | OBLN |
OBALON THERAPEUTICS INC
Common Stock |
C - Conversion | 3,985,970 | 3,985,970 | |||||
2016-09-13 |
|
4 | CLCD |
CoLucid Pharmaceuticals, Inc.
Common Stock |
J - Other | -1,943,109 | 0 | -100.00 | ||||
2016-08-03 |
|
4 | CLCD |
CoLucid Pharmaceuticals, Inc.
Common Stock |
S - Sale | -129 | 3,039 | -4.07 | 8.15 | -1,051 | 24,768 | |
2016-08-03 |
|
4 | CLCD |
CoLucid Pharmaceuticals, Inc.
Common Stock |
S - Sale | -32 | 3,168 | -1.00 | 8.71 | -279 | 27,593 | |
2016-08-03 |
|
4 | CLCD |
CoLucid Pharmaceuticals, Inc.
Common Stock |
S - Sale | -84 | 3,200 | -2.56 | 8.82 | -741 | 28,224 | |
2016-08-03 |
|
4 | CLCD |
CoLucid Pharmaceuticals, Inc.
Common Stock |
S - Sale | -81,094 | 1,943,109 | -4.01 | 8.15 | -660,916 | 15,836,338 | |
2016-08-03 |
|
4 | CLCD |
CoLucid Pharmaceuticals, Inc.
Common Stock |
S - Sale | -19,718 | 2,024,203 | -0.96 | 8.71 | -171,744 | 17,630,808 | |
2016-08-03 |
|
4 | CLCD |
CoLucid Pharmaceuticals, Inc.
Common Stock |
S - Sale | -52,216 | 2,043,921 | -2.49 | 8.82 | -460,545 | 18,027,383 | |
2016-06-13 |
|
4 | CLVS |
Clovis Oncology, Inc.
Stock Option (Right to buy) |
A - Award | 10,000 | 10,000 | |||||
2016-05-27 |
|
4 | EVOK |
Evoke Pharma Inc
Common Stock |
S - Sale | -5,880 | 10,328 | -36.28 | 4.70 | -27,636 | 48,542 | |
2016-05-27 |
|
4 | EVOK |
Evoke Pharma Inc
Common Stock |
S - Sale | -344,120 | 606,283 | -36.21 | 4.70 | -1,617,364 | 2,849,530 | |
2016-05-26 |
|
4 | LIFE |
aTYR PHARMA INC
Stock Option (right to buy) |
A - Award | 18,000 | 18,000 | |||||
2016-05-02 |
|
4 | CLCD |
CoLucid Pharmaceuticals, Inc.
Common Stock |
S - Sale | -149,765 | 2,096,137 | -6.67 | 6.96 | -1,042,364 | 14,589,114 | |
2016-05-02 |
|
4 | CLCD |
CoLucid Pharmaceuticals, Inc.
Common Stock |
S - Sale | -235 | 3,284 | -6.68 | 6.96 | -1,636 | 22,857 | |
2016-04-27 |
|
4 | EVOK |
Evoke Pharma Inc
Common Stock |
S - Sale | -61 | 16,208 | -0.37 | 5.02 | -306 | 81,364 | |
2016-04-27 |
|
4 | EVOK |
Evoke Pharma Inc
Common Stock |
S - Sale | -21 | 16,269 | -0.13 | 5.20 | -109 | 84,599 | |
2016-04-27 |
|
4 | EVOK |
Evoke Pharma Inc
Common Stock |
S - Sale | -3,603 | 950,403 | -0.38 | 5.02 | -18,087 | 4,771,023 | |
2016-04-27 |
|
4 | EVOK |
Evoke Pharma Inc
Common Stock |
S - Sale | -1,492 | 954,006 | -0.16 | 5.20 | -7,758 | 4,960,831 | |
2016-04-21 |
|
4 | EVOK |
Evoke Pharma Inc
Common Stock |
S - Sale | -76 | 16,290 | -0.46 | 5.29 | -402 | 86,174 | |
2016-04-21 |
|
4 | EVOK |
Evoke Pharma Inc
Common Stock |
S - Sale | -632 | 16,366 | -3.72 | 5.36 | -3,388 | 87,722 | |
2016-04-21 |
|
4 | EVOK |
Evoke Pharma Inc
Common Stock |
S - Sale | -4,424 | 955,498 | -0.46 | 5.29 | -23,403 | 5,054,584 | |
2016-04-21 |
|
4 | EVOK |
Evoke Pharma Inc
Common Stock |
S - Sale | -37,054 | 959,922 | -3.72 | 5.36 | -198,609 | 5,145,182 | |
2016-04-13 |
|
4 | EVOK |
Evoke Pharma Inc
Common Stock |
S - Sale | -75 | 16,998 | -0.44 | 5.22 | -392 | 88,730 | |
2016-04-13 |
|
4 | EVOK |
Evoke Pharma Inc
Common Stock |
S - Sale | -4,348 | 996,976 | -0.43 | 5.22 | -22,697 | 5,204,215 | |
2016-04-08 |
|
4 | EVOK |
Evoke Pharma Inc
Common Stock |
S - Sale | -251 | 17,073 | -1.45 | 5.35 | -1,343 | 91,341 | |
2016-04-08 |
|
4 | EVOK |
Evoke Pharma Inc
Common Stock |
S - Sale | -475 | 17,324 | -2.67 | 5.26 | -2,498 | 91,124 | |
2016-04-08 |
|
4 | EVOK |
Evoke Pharma Inc
Common Stock |
S - Sale | -148 | 17,799 | -0.82 | 5.22 | -773 | 92,911 | |
2016-04-08 |
|
4 | EVOK |
Evoke Pharma Inc
Common Stock |
S - Sale | -14,554 | 1,001,324 | -1.43 | 5.35 | -77,864 | 5,357,083 | |
2016-04-08 |
|
4 | EVOK |
Evoke Pharma Inc
Common Stock |
S - Sale | -27,781 | 1,015,878 | -2.66 | 5.26 | -146,128 | 5,343,518 | |
2016-04-08 |
|
4 | EVOK |
Evoke Pharma Inc
Common Stock |
S - Sale | -8,669 | 1,043,659 | -0.82 | 5.22 | -45,252 | 5,447,900 | |
2016-03-08 |
|
4 | SNDX |
Syndax Pharmaceuticals Inc
Series C-1 Preferred Stock |
C - Conversion | -360,640 | 0 | -100.00 | ||||
2016-03-08 |
|
4 | SNDX |
Syndax Pharmaceuticals Inc
Series B-1 Preferred Stock |
C - Conversion | -400,422 | 0 | -100.00 | ||||
2016-03-08 |
|
4 | SNDX |
Syndax Pharmaceuticals Inc
Common Stock |
C - Conversion | 761,062 | 761,062 | |||||
2016-03-08 |
|
4 | SNDX |
Syndax Pharmaceuticals Inc
Series C-1 Preferred Stock |
C - Conversion | -2,674 | 0 | -100.00 | ||||
2016-03-08 |
|
4 | SNDX |
Syndax Pharmaceuticals Inc
Series B-1 Preferred Stock |
C - Conversion | -2,967 | 0 | -100.00 | ||||
2016-03-08 |
|
4 | SNDX |
Syndax Pharmaceuticals Inc
Common Stock |
C - Conversion | 5,641 | 5,641 | |||||
2016-03-08 |
|
4 | SNDX |
Syndax Pharmaceuticals Inc
Series A-1 Preferred Stock |
C - Conversion | -13,925 | 0 | -100.00 | ||||
2016-03-08 |
|
4 | SNDX |
Syndax Pharmaceuticals Inc
Common Stock |
C - Conversion | 13,925 | 13,925 | |||||
2016-03-08 |
|
4 | SNDX |
Syndax Pharmaceuticals Inc
Series B-1 Preferred Stock |
C - Conversion | -444,460 | 0 | -100.00 | ||||
2016-03-08 |
|
4 | SNDX |
Syndax Pharmaceuticals Inc
Series A-1 Preferred Stock |
C - Conversion | -1,299,394 | 0 | -100.00 | ||||
2016-03-08 |
|
4 | SNDX |
Syndax Pharmaceuticals Inc
Common Stock |
C - Conversion | 1,743,854 | 1,743,854 | |||||
2016-03-02 | 3 | SNDX |
Syndax Pharmaceuticals Inc
Common Stock |
27,128 | ||||||||
2016-03-02 | 3 | SNDX |
Syndax Pharmaceuticals Inc
Common Stock |
27,128 | ||||||||
2016-03-02 | 3 | SNDX |
Syndax Pharmaceuticals Inc
Common Stock |
27,128 | ||||||||
2016-03-02 | 3 | SNDX |
Syndax Pharmaceuticals Inc
Common Stock |
27,128 | ||||||||
2016-03-02 | 3 | SNDX |
Syndax Pharmaceuticals Inc
Common Stock |
27,128 | ||||||||
2016-03-02 | 3 | SNDX |
Syndax Pharmaceuticals Inc
Common Stock |
27,128 | ||||||||
2016-03-02 | 3 | SNDX |
Syndax Pharmaceuticals Inc
Common Stock |
27,128 | ||||||||
2016-03-02 | 3 | SNDX |
Syndax Pharmaceuticals Inc
Common Stock |
27,128 | ||||||||
2016-03-02 | 3 | SNDX |
Syndax Pharmaceuticals Inc
Common Stock |
27,128 | ||||||||
2016-01-29 |
|
4 | LIFE |
aTYR PHARMA INC
Stock Option (right to buy) |
A - Award | 19,428 | 19,428 | |||||
2015-09-24 |
|
4 | CLVS |
Clovis Oncology, Inc.
Common Stock |
J - Other | -794,888 | 1,286,857 | -38.18 | ||||
2015-08-20 |
|
4 | EVOK |
Evoke Pharma Inc
Common Stock |
S - Sale | -11,836 | 1,052,328 | -1.11 | 7.02 | -83,089 | 7,387,343 | |
2015-08-20 |
|
4 | EVOK |
Evoke Pharma Inc
Common Stock |
S - Sale | -202 | 17,947 | -1.11 | 7.02 | -1,418 | 125,988 | |
2015-07-17 |
|
4 | CLVS |
Clovis Oncology, Inc.
Common Stock |
J - Other | 2,185 | 2,185 | |||||
2015-07-17 |
|
4 | CLVS |
Clovis Oncology, Inc.
Common Stock |
J - Other | -41,813 | 0 | -100.00 | ||||
2015-07-10 |
|
4 | LIFE |
aTYR PHARMA INC
Stock Option (right to buy) |
A - Award | 6,286 | 6,286 | |||||
2015-07-01 |
|
4 | GKOS |
GLAUKOS Corp
Series F Preferred Stock |
C - Conversion | -286,983 | 0 | -100.00 | ||||
2015-07-01 |
|
4 | GKOS |
GLAUKOS Corp
Series E Preferred Stock |
C - Conversion | -589,100 | 0 | -100.00 | ||||
2015-07-01 |
|
4 | GKOS |
GLAUKOS Corp
Common Stock |
C - Conversion | 876,083 | 876,083 | |||||
2015-07-01 |
|
4 | GKOS |
GLAUKOS Corp
Series F Preferred Stock |
C - Conversion | -2,130 | 0 | -100.00 | ||||
2015-07-01 |
|
4 | GKOS |
GLAUKOS Corp
Series E Preferred Stock |
C - Conversion | -4,371 | 0 | -100.00 | ||||
2015-07-01 |
|
4 | GKOS |
GLAUKOS Corp
Common Stock |
C - Conversion | 6,501 | 6,501 | |||||
2015-07-01 |
|
4 | GKOS |
GLAUKOS Corp
Warrant |
M - Exercise | -20,470 | 0 | -100.00 | ||||
2015-07-01 |
|
4 | GKOS |
GLAUKOS Corp
Series D Preferred Stock |
C - Conversion | -105,128 | 0 | -100.00 | ||||
2015-07-01 |
|
4 | GKOS |
GLAUKOS Corp
Series C Preferred Stock |
C - Conversion | -440,178 | 0 | -100.00 | ||||
2015-07-01 |
|
4 | GKOS |
GLAUKOS Corp
Series B Preferred Stock |
C - Conversion | -925,926 | 0 | -100.00 | ||||
2015-07-01 |
|
4 | GKOS |
GLAUKOS Corp
Series A Preferred Stock |
C - Conversion | -585,958 | 0 | -100.00 | ||||
2015-07-01 |
|
4 | GKOS |
GLAUKOS Corp
Common Stock |
F - Taxes | -8,700 | 2,068,960 | -0.42 | 18.00 | -156,600 | 37,241,280 | |
2015-07-01 |
|
4 | GKOS |
GLAUKOS Corp
Common Stock |
M - Exercise | 20,470 | 2,077,660 | 1.00 | 7.65 | 156,596 | 15,894,099 | |
2015-07-01 |
|
4 | GKOS |
GLAUKOS Corp
Common Stock |
C - Conversion | 2,057,190 | 2,057,190 | |||||
2015-07-01 |
|
4 | GKOS |
GLAUKOS Corp
Series A Preferred Stock |
C - Conversion | -14,041 | 0 | -100.00 | ||||
2015-07-01 |
|
4 | GKOS |
GLAUKOS Corp
Common Stock |
C - Conversion | 14,041 | 14,041 | |||||
2015-06-24 | 3 | GKOS |
GLAUKOS Corp
Common Stock |
126,400 | ||||||||
2015-06-24 | 3 | GKOS |
GLAUKOS Corp
Common Stock |
126,400 | ||||||||
2015-06-24 | 3 | GKOS |
GLAUKOS Corp
Common Stock |
126,400 | ||||||||
2015-06-24 | 3 | GKOS |
GLAUKOS Corp
Common Stock |
126,400 | ||||||||
2015-06-24 | 3 | GKOS |
GLAUKOS Corp
Common Stock |
126,400 | ||||||||
2015-06-24 | 3 | GKOS |
GLAUKOS Corp
Common Stock |
126,400 | ||||||||
2015-06-24 | 3 | GKOS |
GLAUKOS Corp
Common Stock |
126,400 | ||||||||
2015-06-24 | 3 | GKOS |
GLAUKOS Corp
Common Stock |
126,400 | ||||||||
2015-06-24 | 3 | GKOS |
GLAUKOS Corp
Common Stock |
126,400 | ||||||||
2015-06-15 |
|
4 | CLVS |
Clovis Oncology, Inc.
Stock Option (Right to buy) |
A - Award | 10,000 | 10,000 | |||||
2015-05-12 |
|
4 | LIFE |
aTYR PHARMA INC
Series E Preferred Stock |
C - Conversion | -887,073 | 0 | -100.00 | ||||
2015-05-12 |
|
4 | LIFE |
aTYR PHARMA INC
Series D Preferred Stock |
C - Conversion | -1,506,901 | 0 | -100.00 | ||||
2015-05-12 |
|
4 | LIFE |
aTYR PHARMA INC
Series C Preferred Stock |
C - Conversion | -12,143,933 | 0 | -100.00 | ||||
2015-05-12 |
|
4 | LIFE |
aTYR PHARMA INC
Common Stock |
C - Conversion | 1,807,820 | 1,807,820 | |||||
2015-05-12 |
|
4 | LIFE |
aTYR PHARMA INC
Series E Preferred Stock |
C - Conversion | -6,581 | 0 | -100.00 | ||||
2015-05-12 |
|
4 | LIFE |
aTYR PHARMA INC
Series D Preferred Stock |
C - Conversion | -11,182 | 0 | -100.00 | ||||
2015-05-12 |
|
4 | LIFE |
aTYR PHARMA INC
Series C Preferred Stock |
C - Conversion | -90,110 | 0 | -100.00 | ||||
2015-05-12 |
|
4 | LIFE |
aTYR PHARMA INC
Common Stock |
C - Conversion | 13,414 | 13,414 | |||||
2015-05-11 |
|
4 | CLCD |
CoLucid Pharmaceuticals, Inc.
Series B Preferred Stock |
C - Conversion | -1,565 | 0 | -100.00 | ||||
2015-05-11 |
|
4 | CLCD |
CoLucid Pharmaceuticals, Inc.
Series A Preferred Stock |
C - Conversion | -1,954 | 0 | -100.00 | ||||
2015-05-11 |
|
4 | CLCD |
CoLucid Pharmaceuticals, Inc.
Common Stock |
C - Conversion | 3,519 | 3,519 | |||||
2015-05-11 |
|
4 | CLCD |
CoLucid Pharmaceuticals, Inc.
Series C Preferred Stock |
C - Conversion | -464,756 | 0 | -100.00 | ||||
2015-05-11 |
|
4 | CLCD |
CoLucid Pharmaceuticals, Inc.
Series B Preferred Stock |
C - Conversion | -939,289 | 0 | -100.00 | ||||
2015-05-11 |
|
4 | CLCD |
CoLucid Pharmaceuticals, Inc.
Series A Preferred Stock |
C - Conversion | -798,188 | 0 | -100.00 | ||||
2015-05-11 |
|
4 | CLCD |
CoLucid Pharmaceuticals, Inc.
Common Stock |
C - Conversion | 2,202,233 | 2,245,902 | 5,043.01 | ||||
2015-05-06 |
|
4 | TBRA |
Tibira Therapeutics, Inc.
Common Stock |
J - Other | 36,187 | 38,094 | 1,897.59 | ||||
2015-05-06 |
|
4 | TBRA |
Regado Biosciences Inc
Common Stock |
P - Purchase | 277,777 | 3,553,322 | 8.48 | 10.62 | 2,949,992 | 37,736,280 | |
2015-05-06 | 3 | TBRA |
Regado Biosciences Inc
Common Stock |
6,551,090 | ||||||||
2015-05-06 | 3 | TBRA |
Regado Biosciences Inc
Common Stock |
6,551,090 | ||||||||
2015-05-06 | 3 | TBRA |
Regado Biosciences Inc
Common Stock |
6,551,090 | ||||||||
2015-05-06 | 3 | TBRA |
Regado Biosciences Inc
Common Stock |
6,551,090 | ||||||||
2015-05-06 | 3 | TBRA |
Regado Biosciences Inc
Common Stock |
6,551,090 | ||||||||
2015-05-06 | 3 | TBRA |
Regado Biosciences Inc
Common Stock |
6,551,090 | ||||||||
2015-05-06 | 3 | TBRA |
Regado Biosciences Inc
Common Stock |
6,551,090 | ||||||||
2015-05-06 | 3 | TBRA |
Regado Biosciences Inc
Common Stock |
6,551,090 | ||||||||
2015-05-06 | 3 | TBRA |
Tibira Therapeutics, Inc.
Common Stock |
95,226 | ||||||||
2015-05-06 | 3 | TBRA |
Tibira Therapeutics, Inc.
Common Stock |
95,226 | ||||||||
2015-05-06 | 3 | TBRA |
Tibira Therapeutics, Inc.
Common Stock |
95,226 | ||||||||
2015-05-06 | 3 | TBRA |
Tibira Therapeutics, Inc.
Common Stock |
95,226 | ||||||||
2015-05-06 | 3 | TBRA |
Tibira Therapeutics, Inc.
Common Stock |
95,226 | ||||||||
2015-05-06 | 3 | TBRA |
Tibira Therapeutics, Inc.
Common Stock |
95,226 | ||||||||
2015-05-06 | 3 | TBRA |
Tibira Therapeutics, Inc.
Common Stock |
95,226 | ||||||||
2015-05-06 | 3 | TBRA |
Tibira Therapeutics, Inc.
Common Stock |
95,226 | ||||||||
2015-05-06 | 3 | LIFE |
aTYR PHARMA INC
Common Stock |
18,858 | ||||||||
2015-05-06 | 3 | LIFE |
aTYR PHARMA INC
Common Stock |
18,858 | ||||||||
2015-05-06 | 3 | LIFE |
aTYR PHARMA INC
Common Stock |
18,858 | ||||||||
2015-05-06 | 3 | LIFE |
aTYR PHARMA INC
Common Stock |
18,858 | ||||||||
2015-05-06 | 3 | LIFE |
aTYR PHARMA INC
Common Stock |
18,858 | ||||||||
2015-05-06 | 3 | LIFE |
aTYR PHARMA INC
Common Stock |
18,858 | ||||||||
2015-05-06 | 3 | LIFE |
aTYR PHARMA INC
Common Stock |
18,858 | ||||||||
2015-05-06 | 3 | LIFE |
aTYR PHARMA INC
Common Stock |
18,858 | ||||||||
2015-05-06 | 3 | LIFE |
aTYR PHARMA INC
Common Stock |
18,858 | ||||||||
2015-05-06 | 3 | LIFE |
aTYR PHARMA INC
Common Stock |
18,858 | ||||||||
2015-05-06 | 3 | LIFE |
aTYR PHARMA INC
Common Stock |
18,858 | ||||||||
2015-05-06 | 3 | LIFE |
aTYR PHARMA INC
Common Stock |
18,858 | ||||||||
2015-05-06 | 3 | LIFE |
aTYR PHARMA INC
Common Stock |
18,858 | ||||||||
2015-05-06 | 3 | LIFE |
aTYR PHARMA INC
Common Stock |
18,858 | ||||||||
2015-05-06 | 3 | LIFE |
aTYR PHARMA INC
Common Stock |
18,858 | ||||||||
2015-05-06 | 3 | LIFE |
aTYR PHARMA INC
Common Stock |
18,858 | ||||||||
2015-05-06 | 3 | LIFE |
aTYR PHARMA INC
Common Stock |
18,858 | ||||||||
2015-05-06 | 3 | LIFE |
aTYR PHARMA INC
Common Stock |
18,858 | ||||||||
2015-05-05 | 3 | CLCD |
CoLucid Pharmaceuticals, Inc.
Common Stock |
87,338 | ||||||||
2015-05-05 | 3 | CLCD |
CoLucid Pharmaceuticals, Inc.
Common Stock |
87,338 | ||||||||
2015-05-05 | 3 | CLCD |
CoLucid Pharmaceuticals, Inc.
Common Stock |
87,338 | ||||||||
2015-05-05 | 3 | CLCD |
CoLucid Pharmaceuticals, Inc.
Common Stock |
87,338 | ||||||||
2015-05-05 | 3 | CLCD |
CoLucid Pharmaceuticals, Inc.
Common Stock |
87,338 | ||||||||
2015-05-05 | 3 | CLCD |
CoLucid Pharmaceuticals, Inc.
Common Stock |
87,338 | ||||||||
2015-05-05 | 3 | CLCD |
CoLucid Pharmaceuticals, Inc.
Common Stock |
87,338 | ||||||||
2015-04-16 |
|
4 | EVOK |
Evoke Pharma Inc
Common Stock |
S - Sale | -32,411 | 1,064,164 | -2.96 | 7.07 | -229,146 | 7,523,639 | |
2015-04-16 |
|
4 | EVOK |
Evoke Pharma Inc
Common Stock |
S - Sale | -7,920 | 1,096,575 | -0.72 | 7.58 | -60,034 | 8,312,038 | |
2015-04-16 |
|
4 | EVOK |
Evoke Pharma Inc
Common Stock |
S - Sale | -9,832 | 1,104,495 | -0.88 | 7.78 | -76,493 | 8,592,971 | |
2015-04-16 |
|
4 | EVOK |
Evoke Pharma Inc
Common Stock |
S - Sale | -554 | 18,149 | -2.96 | 7.07 | -3,917 | 128,313 | |
2015-04-16 |
|
4 | EVOK |
Evoke Pharma Inc
Common Stock |
S - Sale | -135 | 18,703 | -0.72 | 7.58 | -1,023 | 141,769 | |
2015-04-16 |
|
4 | EVOK |
Evoke Pharma Inc
Common Stock |
S - Sale | -168 | 18,838 | -0.88 | 7.78 | -1,307 | 146,560 | |
2015-03-24 |
|
4 | ESPR |
Esperion Therapeutics, Inc.
Common Stock |
J - Other | -350,000 | 2,216,935 | -13.63 | ||||
2015-03-05 |
|
4 | CLVS |
Clovis Oncology, Inc.
Common Stock |
S - Sale | -8,528 | 35,506 | -19.37 | 77.70 | -662,626 | 2,758,816 | |
2015-03-05 |
|
4 | CLVS |
Clovis Oncology, Inc.
Common Stock |
J - Other | -500,000 | 2,081,745 | -19.37 | ||||
2014-12-10 |
|
4/A | NEOT |
Neothetics, Inc.
Series C Preferred Stock Warrant (Right to Buy) |
M - Exercise | -2,827 | 0 | -100.00 | ||||
2014-12-10 |
|
4/A | NEOT |
Neothetics, Inc.
Series B-2 Preferred Stock Warrant (Right to Buy) |
M - Exercise | -1,570 | 0 | -100.00 | ||||
2014-12-10 |
|
4/A | NEOT |
Neothetics, Inc.
Series C Preferred Stock |
C - Conversion | -102,282 | 0 | -100.00 | ||||
2014-12-10 |
|
4/A | NEOT |
Neothetics, Inc.
Series B-2 Preferred Stock |
C - Conversion | -36,913 | 0 | -100.00 | ||||
2014-12-10 |
|
4/A | NEOT |
Neothetics, Inc.
Series B Preferred Stock |
C - Conversion | -104,247 | 0 | -100.00 | ||||
2014-12-10 |
|
4/A | NEOT |
Neothetics, Inc.
Series A Preferred Stock |
C - Conversion | -12,578 | 0 | -100.00 | ||||
2014-12-10 |
|
4/A | NEOT |
Neothetics, Inc.
Common Stock |
F - Taxes | -1,725 | 48,025 | -3.47 | 14.00 | -24,150 | 672,350 | |
2014-12-10 |
|
4/A | NEOT |
Neothetics, Inc.
Common Stock |
M - Exercise | 2,827 | 49,750 | 6.02 | 8.54 | 24,143 | 424,865 | |
2014-12-10 |
|
4/A | NEOT |
Neothetics, Inc.
Common Stock |
F - Taxes | -958 | 46,923 | -2.00 | 14.00 | -13,412 | 656,922 | |
2014-12-10 |
|
4/A | NEOT |
Neothetics, Inc.
Common Stock |
M - Exercise | 1,570 | 47,881 | 3.39 | 8.54 | 13,408 | 408,904 | |
2014-12-10 |
|
4/A | NEOT |
Neothetics, Inc.
Common Stock |
C - Conversion | 46,311 | 46,311 | |||||
2014-12-10 |
|
4/A | NEOT |
Neothetics, Inc.
Series C Preferred Stock Warrant (Right to Buy) |
M - Exercise | -165,790 | 0 | -100.00 | ||||
2014-12-10 |
|
4/A | NEOT |
Neothetics, Inc.
Series B-2 Preferred Stock Warrant (Right to Buy) |
M - Exercise | -92,105 | 0 | -100.00 | ||||
2014-12-10 |
|
4/A | NEOT |
Neothetics, Inc.
Series C Preferred Stock |
C - Conversion | -7,252,144 | 0 | -100.00 | ||||
2014-12-10 |
|
4/A | NEOT |
Neothetics, Inc.
Series B-2 Preferred Stock |
C - Conversion | -2,164,305 | 0 | -100.00 | ||||
2014-12-10 |
|
4/A | NEOT |
Neothetics, Inc.
Series B Preferred Stock |
C - Conversion | -6,111,968 | 0 | -100.00 | ||||
2014-12-10 |
|
4/A | NEOT |
Neothetics, Inc.
Series A Preferred Stock |
C - Conversion | -737,422 | 0 | -100.00 | ||||
2014-12-10 |
|
4/A | NEOT |
Neothetics, Inc.
Common Stock |
P - Purchase | 70,000 | 3,091,643 | 2.32 | 14.00 | 980,000 | 43,283,002 | |
2014-12-10 |
|
4/A | NEOT |
Neothetics, Inc.
Common Stock |
F - Taxes | -101,132 | 3,021,643 | -3.24 | 14.00 | -1,415,848 | 42,303,002 | |
2014-12-10 |
|
4/A | NEOT |
Neothetics, Inc.
Common Stock |
M - Exercise | 165,790 | 3,122,775 | 5.61 | 8.54 | 1,415,847 | 26,668,498 | |
2014-12-10 |
|
4/A | NEOT |
Neothetics, Inc.
Common Stock |
F - Taxes | -56,185 | 2,956,985 | -1.86 | 14.00 | -786,590 | 41,397,790 | |
2014-12-10 |
|
4/A | NEOT |
Neothetics, Inc.
Common Stock |
M - Exercise | 92,105 | 3,013,170 | 3.15 | 8.54 | 786,577 | 25,732,472 | |
2014-12-10 |
|
4/A | NEOT |
Neothetics, Inc.
Common Stock |
C - Conversion | 2,921,065 | 2,921,065 | |||||
2014-11-26 |
|
4 | NEOT |
Neothetics, Inc.
Series C Preferred Stock Warrant (Right to Buy) |
M - Exercise | -165,790 | 0 | -100.00 | ||||
2014-11-26 |
|
4 | NEOT |
Neothetics, Inc.
Series B-2 Preferred Stock Warrant (Right to Buy) |
M - Exercise | -92,105 | 0 | -100.00 | ||||
2014-11-26 |
|
4 | NEOT |
Neothetics, Inc.
Series C Preferred Stock |
C - Conversion | -7,252,144 | 0 | -100.00 | ||||
2014-11-26 |
|
4 | NEOT |
Neothetics, Inc.
Series B-2 Preferred Stock |
C - Conversion | -2,164,305 | 0 | -100.00 | ||||
2014-11-26 |
|
4 | NEOT |
Neothetics, Inc.
Series B Preferred Stock |
C - Conversion | -6,111,968 | 0 | -100.00 | ||||
2014-11-26 |
|
4 | NEOT |
Neothetics, Inc.
Series A Preferred Stock |
C - Conversion | -737,422 | 0 | -100.00 | ||||
2014-11-26 |
|
4 | NEOT |
Neothetics, Inc.
Common Stock |
P - Purchase | 70,000 | 3,091,642 | 2.32 | 14.00 | 980,000 | 43,282,988 | |
2014-11-26 |
|
4 | NEOT |
Neothetics, Inc.
Common Stock |
F - Taxes | -101,132 | 3,021,642 | -3.24 | 14.00 | -1,415,848 | 42,302,988 | |
2014-11-26 |
|
4 | NEOT |
Neothetics, Inc.
Common Stock |
M - Exercise | 165,790 | 3,122,774 | 5.61 | 8.54 | 1,415,847 | 26,668,490 | |
2014-11-26 |
|
4 | NEOT |
Neothetics, Inc.
Common Stock |
F - Taxes | -56,185 | 2,956,984 | -1.86 | 14.00 | -786,590 | 41,397,776 | |
2014-11-26 |
|
4 | NEOT |
Neothetics, Inc.
Common Stock |
M - Exercise | 92,105 | 3,013,169 | 3.15 | 8.54 | 786,577 | 25,732,463 | |
2014-11-26 |
|
4 | NEOT |
Neothetics, Inc.
Common Stock |
C - Conversion | 2,921,064 | 2,921,064 | |||||
2014-11-26 |
|
4 | NEOT |
Neothetics, Inc.
Series C Preferred Stock Warrant (Right to Buy) |
M - Exercise | -2,827 | 0 | -100.00 | ||||
2014-11-26 |
|
4 | NEOT |
Neothetics, Inc.
Series B-2 Preferred Stock Warrant (Right to Buy) |
M - Exercise | -1,570 | 0 | -100.00 | ||||
2014-11-26 |
|
4 | NEOT |
Neothetics, Inc.
Series C Preferred Stock |
C - Conversion | -102,282 | 0 | -100.00 | ||||
2014-11-26 |
|
4 | NEOT |
Neothetics, Inc.
Series B-2 Preferred Stock |
C - Conversion | -36,913 | 0 | -100.00 | ||||
2014-11-26 |
|
4 | NEOT |
Neothetics, Inc.
Series B Preferred Stock |
C - Conversion | -104,247 | 0 | -100.00 | ||||
2014-11-26 |
|
4 | NEOT |
Neothetics, Inc.
Series A Preferred Stock |
C - Conversion | -12,578 | 0 | -100.00 | ||||
2014-11-26 |
|
4 | NEOT |
Neothetics, Inc.
Common Stock |
F - Taxes | -1,725 | 48,023 | -3.47 | 14.00 | -24,150 | 672,322 | |
2014-11-26 |
|
4 | NEOT |
Neothetics, Inc.
Common Stock |
M - Exercise | 2,827 | 49,748 | 6.03 | 8.54 | 24,143 | 424,848 | |
2014-11-26 |
|
4 | NEOT |
Neothetics, Inc.
Common Stock |
F - Taxes | -958 | 46,921 | -2.00 | 14.00 | -13,412 | 656,894 | |
2014-11-26 |
|
4 | NEOT |
Neothetics, Inc.
Common Stock |
M - Exercise | 1,570 | 47,879 | 3.39 | 8.54 | 13,408 | 408,887 | |
2014-11-26 |
|
4 | NEOT |
Neothetics, Inc.
Common Stock |
C - Conversion | 46,309 | 46,309 | |||||
2014-11-19 | 3 | NEOT |
Neothetics, Inc.
Common Stock |
7,868 | ||||||||
2014-11-19 | 3 | NEOT |
Neothetics, Inc.
Common Stock |
7,868 | ||||||||
2014-11-19 | 3 | NEOT |
Neothetics, Inc.
Common Stock |
7,868 | ||||||||
2014-11-19 | 3 | NEOT |
Neothetics, Inc.
Common Stock |
7,868 | ||||||||
2014-11-19 | 3 | NEOT |
Neothetics, Inc.
Common Stock |
7,868 | ||||||||
2014-11-19 | 3 | NEOT |
Neothetics, Inc.
Common Stock |
7,868 | ||||||||
2014-11-19 | 3 | NEOT |
Neothetics, Inc.
Common Stock |
7,868 | ||||||||
2014-11-19 | 3 | NEOT |
Neothetics, Inc.
Common Stock |
7,868 | ||||||||
2014-11-19 | 3 | NEOT |
Neothetics, Inc.
Common Stock |
7,868 | ||||||||
2014-11-18 |
|
4 | DRTX |
Durata Therapeutics, Inc.
Common Stock |
D - Sale to Issuer | -6,250 | 0 | -100.00 | ||||
2014-11-18 |
|
4 | DRTX |
Durata Therapeutics, Inc.
Common Stock |
D - Sale to Issuer | -22,306 | 0 | -100.00 | ||||
2014-11-18 |
|
4 | DRTX |
Durata Therapeutics, Inc.
Common Stock |
D - Sale to Issuer | -3,006,132 | 0 | -100.00 | ||||
2014-10-21 |
|
4 | ESPR |
Esperion Therapeutics, Inc.
Common Stock |
P - Purchase | 500,000 | 2,566,935 | 24.19 | 20.00 | 10,000,000 | 51,338,700 | |
2014-10-21 |
|
4 | ATRA |
Atara Biotherapeutics, Inc.
Series B Preferred Stock |
C - Conversion | -4,606 | 0 | -100.00 | ||||
2014-10-21 |
|
4 | ATRA |
Atara Biotherapeutics, Inc.
Series A Preferred Stock |
C - Conversion | -9,443 | 0 | -100.00 | ||||
2014-10-21 |
|
4 | ATRA |
Atara Biotherapeutics, Inc.
Common Stock |
P - Purchase | 1,841 | 15,890 | 13.10 | 11.00 | 20,251 | 174,790 | |
2014-10-21 |
|
4 | ATRA |
Atara Biotherapeutics, Inc.
Common Stock |
C - Conversion | 14,049 | 14,049 | |||||
2014-10-21 |
|
4 | ATRA |
Atara Biotherapeutics, Inc.
Series B Preferred Stock |
C - Conversion | -620,776 | 0 | -100.00 | ||||
2014-10-21 |
|
4 | ATRA |
Atara Biotherapeutics, Inc.
Series A Preferred Stock |
C - Conversion | -1,272,607 | 0 | -100.00 | ||||
2014-10-21 |
|
4 | ATRA |
Atara Biotherapeutics, Inc.
Common Stock |
P - Purchase | 248,159 | 2,141,542 | 13.11 | 11.00 | 2,729,749 | 23,556,962 | |
2014-10-21 |
|
4 | ATRA |
Atara Biotherapeutics, Inc.
Common Stock |
C - Conversion | 1,893,383 | 1,893,383 | |||||
2014-09-12 |
|
4 | VCYT |
VERACYTE, INC.
Common Stock |
J - Other | -300,000 | 2,763,294 | -9.79 | ||||
2014-08-18 |
|
4 | OTIC |
Otonomy, Inc.
Series C Preferred Stock Warrant (Right to Buy) |
M - Exercise | -502 | 0 | -100.00 | ||||
2014-08-18 |
|
4 | OTIC |
Otonomy, Inc.
Series D Preferred Stock |
F - Taxes | -1,386 | 0 | -100.00 | ||||
2014-08-18 |
|
4 | OTIC |
Otonomy, Inc.
Series C Preferred Stock |
C - Conversion | -6,866 | 0 | -100.00 | ||||
2014-08-18 |
|
4 | OTIC |
Otonomy, Inc.
Series B Preferred Stock |
C - Conversion | -3,238 | 0 | -100.00 | ||||
2014-08-18 |
|
4 | OTIC |
Otonomy, Inc.
Common Stock |
F - Taxes | -277 | 11,715 | -2.31 | 16.00 | -4,432 | 187,440 | |
2014-08-18 |
|
4 | OTIC |
Otonomy, Inc.
Common Stock |
M - Exercise | 502 | 11,992 | 4.37 | 8.79 | 4,413 | 105,410 | |
2014-08-18 |
|
4 | OTIC |
Otonomy, Inc.
Common Stock |
C - Conversion | 11,490 | 11,490 | |||||
2014-08-18 |
|
4 | OTIC |
Otonomy, Inc.
Series C Preferred Stock Warrant (Right to Buy) |
M - Exercise | -67,755 | 0 | -100.00 | ||||
2014-08-18 |
|
4 | OTIC |
Otonomy, Inc.
Series D Preferred Stock |
F - Taxes | -186,828 | 0 | -100.00 | ||||
2014-08-18 |
|
4 | OTIC |
Otonomy, Inc.
Series C Preferred Stock |
C - Conversion | -925,479 | 0 | -100.00 | ||||
2014-08-18 |
|
4 | OTIC |
Otonomy, Inc.
Series B Preferred Stock |
C - Conversion | -436,485 | 0 | -100.00 | ||||
2014-08-18 |
|
4 | OTIC |
Otonomy, Inc.
Common Stock |
F - Taxes | -37,224 | 1,579,323 | -2.30 | 16.00 | -595,584 | 25,269,168 | |
2014-08-18 |
|
4 | OTIC |
Otonomy, Inc.
Common Stock |
M - Exercise | 67,755 | 1,616,547 | 4.37 | 8.79 | 595,566 | 14,209,448 | |
2014-08-18 |
|
4 | OTIC |
Otonomy, Inc.
Common Stock |
C - Conversion | 1,548,792 | 1,548,792 | |||||
2014-08-07 |
|
4 | MRNS |
MARINUS PHARMACEUTICALS INC
Series C Preferred Stock |
C - Conversion | -1,165 | 0 | -100.00 | ||||
2014-08-07 |
|
4 | MRNS |
MARINUS PHARMACEUTICALS INC
Series B Preferred Stock |
C - Conversion | -7,043 | 0 | -100.00 | ||||
2014-08-07 |
|
4 | MRNS |
MARINUS PHARMACEUTICALS INC
Series A Preferred Stock |
C - Conversion | -8,792 | 0 | -100.00 | ||||
2014-08-07 |
|
4 | MRNS |
MARINUS PHARMACEUTICALS INC
Common Stock |
C - Conversion | 17,000 | 17,000 | |||||
2014-08-07 |
|
4 | MRNS |
MARINUS PHARMACEUTICALS INC
Series C Preferred Stock |
C - Conversion | -579,630 | 0 | -100.00 | ||||
2014-08-07 |
|
4 | MRNS |
MARINUS PHARMACEUTICALS INC
Series B Preferred Stock |
C - Conversion | -657,192 | 0 | -100.00 | ||||
2014-08-07 |
|
4 | MRNS |
MARINUS PHARMACEUTICALS INC
Series A Preferred Stock |
C - Conversion | -820,320 | 0 | -100.00 | ||||
2014-08-07 |
|
4 | MRNS |
MARINUS PHARMACEUTICALS INC
Common Stock |
P - Purchase | 419,744 | 2,476,886 | 20.40 | 8.00 | 3,357,952 | 19,815,088 | |
2014-08-07 |
|
4 | MRNS |
MARINUS PHARMACEUTICALS INC
Common Stock |
C - Conversion | 2,057,142 | 2,057,142 | |||||
2014-07-31 | 3 | MRNS |
MARINUS PHARMACEUTICALS INC
Common Stock |
85,100 | ||||||||
2014-07-31 | 3 | MRNS |
MARINUS PHARMACEUTICALS INC
Common Stock |
85,100 | ||||||||
2014-07-31 | 3 | MRNS |
MARINUS PHARMACEUTICALS INC
Common Stock |
85,100 | ||||||||
2014-07-31 | 3 | MRNS |
MARINUS PHARMACEUTICALS INC
Common Stock |
85,100 | ||||||||
2014-07-31 | 3 | MRNS |
MARINUS PHARMACEUTICALS INC
Common Stock |
85,100 | ||||||||
2014-07-31 | 3 | MRNS |
MARINUS PHARMACEUTICALS INC
Common Stock |
85,100 | ||||||||
2014-07-31 | 3 | MRNS |
MARINUS PHARMACEUTICALS INC
Common Stock |
85,100 | ||||||||
2014-07-31 | 3 | MRNS |
MARINUS PHARMACEUTICALS INC
Common Stock |
85,100 | ||||||||
2014-07-31 | 3 | MRNS |
MARINUS PHARMACEUTICALS INC
Common Stock |
85,100 | ||||||||
2014-06-19 |
|
4 | CLVS |
Clovis Oncology, Inc.
Stock Option (Right to buy) |
A - Award | 12,414 | 12,414 | |||||
2014-05-22 |
|
4 | ZGNX |
ZOGENIX, INC.
Stock Option (Right to Buy) |
A - Award | 50,000 | 50,000 | |||||
2014-05-07 |
|
4 | ALDX |
Aldeyra Therapeutics, Inc.
Convertible Promissory Note |
C - Conversion | 0 | ||||||
2014-05-07 |
|
4 | ALDX |
Aldeyra Therapeutics, Inc.
Common Stock |
C - Conversion | 21,250 | 1,973,389 | 1.09 | ||||
2014-05-05 |
|
4 | ALDX |
Aldeyra Therapeutics, Inc.
Series A Preferred Stock |
C - Conversion | -3,882 | 0 | -100.00 | ||||
2014-05-05 |
|
4 | ALDX |
Aldeyra Therapeutics, Inc.
Common Stock |
C - Conversion | 9,208 | 9,208 | |||||
2014-05-05 |
|
4 | ALDX |
Aldeyra Therapeutics, Inc.
Series B Preferred Stock Warrant (Right to Buy) |
M - Exercise | -60,576 | 0 | -100.00 | ||||
2014-05-05 |
|
4 | ALDX |
Aldeyra Therapeutics, Inc.
Series B Preferred Stock Warrant (Right to Buy) |
M - Exercise | -60,576 | 0 | -100.00 | ||||
2014-05-05 |
|
4 | ALDX |
Aldeyra Therapeutics, Inc.
Series B Preferred Stock |
C - Conversion | -755,263 | 0 | -100.00 | ||||
2014-05-05 |
|
4 | ALDX |
Aldeyra Therapeutics, Inc.
Series A Preferred Stock |
C - Conversion | -486,316 | 0 | -100.00 | ||||
2014-05-05 |
|
4 | ALDX |
Aldeyra Therapeutics, Inc.
Common Stock |
F - Taxes | -39,063 | 1,952,139 | -1.96 | 8.00 | -312,504 | 15,617,112 | |
2014-05-05 |
|
4 | ALDX |
Aldeyra Therapeutics, Inc.
Common Stock |
F - Taxes | -39,063 | 1,952,139 | -1.96 | 8.00 | -312,504 | 15,617,112 | |
2014-05-05 |
|
4 | ALDX |
Aldeyra Therapeutics, Inc.
Common Stock |
M - Exercise | 60,576 | 1,991,202 | 3.14 | 5.16 | 312,572 | 10,274,602 | |
2014-05-05 |
|
4 | ALDX |
Aldeyra Therapeutics, Inc.
Common Stock |
M - Exercise | 60,576 | 1,991,202 | 3.14 | 5.16 | 312,572 | 10,274,602 | |
2014-05-05 |
|
4 | ALDX |
Aldeyra Therapeutics, Inc.
Common Stock |
C - Conversion | 1,909,113 | 1,909,113 | |||||
2014-05-01 | 3 | ALDX |
Aldeyra Therapeutics, Inc.
Common Stock |
20,716 | ||||||||
2014-05-01 | 3 | ALDX |
Aldeyra Therapeutics, Inc.
Common Stock |
20,716 | ||||||||
2014-05-01 | 3 | ALDX |
Aldeyra Therapeutics, Inc.
Common Stock |
20,716 | ||||||||
2014-05-01 | 3 | ALDX |
Aldeyra Therapeutics, Inc.
Common Stock |
20,716 | ||||||||
2014-05-01 | 3 | ALDX |
Aldeyra Therapeutics, Inc.
Common Stock |
20,716 | ||||||||
2014-05-01 | 3 | ALDX |
Aldeyra Therapeutics, Inc.
Common Stock |
20,716 | ||||||||
2014-05-01 | 3 | ALDX |
Aldeyra Therapeutics, Inc.
Common Stock |
20,716 | ||||||||
2014-05-01 | 3 | ALDX |
Aldeyra Therapeutics, Inc.
Common Stock |
20,716 | ||||||||
2014-05-01 | 3 | ALDX |
Aldeyra Therapeutics, Inc.
Common Stock |
20,716 | ||||||||
2014-03-21 |
|
4 | CADX |
CADENCE PHARMACEUTICALS INC
Stock Option (Right to Buy) |
D - Sale to Issuer | -25,000 | 0 | -100.00 | 6.79 | -169,750 | ||
2014-03-21 |
|
4 | CADX |
CADENCE PHARMACEUTICALS INC
Stock Option (Right to Buy) |
D - Sale to Issuer | -17,500 | 0 | -100.00 | 11.02 | -192,850 | ||
2014-03-21 |
|
4 | CADX |
CADENCE PHARMACEUTICALS INC
Stock Option (Right to Buy) |
D - Sale to Issuer | -12,500 | 0 | -100.00 | 4.75 | -59,375 | ||
2014-03-21 |
|
4 | CADX |
CADENCE PHARMACEUTICALS INC
Stock Option (Right to Buy) |
D - Sale to Issuer | -12,500 | 0 | -100.00 | 6.84 | -85,500 | ||
2014-03-21 |
|
4 | CADX |
CADENCE PHARMACEUTICALS INC
Stock Option (Right to Buy) |
D - Sale to Issuer | -12,500 | 0 | -100.00 | 4.63 | -57,875 | ||
2014-03-21 |
|
4 | CADX |
CADENCE PHARMACEUTICALS INC
Stock Option (Right to Buy) |
D - Sale to Issuer | -12,500 | 0 | -100.00 | 7.65 | -95,625 | ||
2014-03-21 |
|
4 | CADX |
CADENCE PHARMACEUTICALS INC
Stock Option (Right to Buy) |
D - Sale to Issuer | -12,500 | 0 | -100.00 | 1.70 | -21,250 | ||
2014-03-21 |
|
4 | CADX |
CADENCE PHARMACEUTICALS INC
Common Stock |
D - Sale to Issuer | -27,500 | 0 | -100.00 | 14.00 | -385,000 | ||
2014-03-21 |
|
4 | CADX |
CADENCE PHARMACEUTICALS INC
Common Stock |
D - Sale to Issuer | -78,369 | 0 | -100.00 | 14.00 | -1,097,166 | ||
2014-03-21 |
|
4 | CADX |
CADENCE PHARMACEUTICALS INC
Common Stock |
D - Sale to Issuer | -7,313,241 | 0 | -100.00 | 14.00 | -102,385,374 | ||
2014-03-21 |
|
4 | CADX |
CADENCE PHARMACEUTICALS INC
Common Stock |
D - Sale to Issuer | -50,743 | 0 | -100.00 | 14.00 | -710,402 | ||
2014-03-21 |
|
4 | CADX |
CADENCE PHARMACEUTICALS INC
Common Stock |
D - Sale to Issuer | -2,972,678 | 0 | -100.00 | 14.00 | -41,617,492 | ||
2014-03-17 |
|
4 | AKAO |
Achaogen Inc
Series D Preferred Stock |
C - Conversion | -7,430 | 0 | -100.00 | ||||
2014-03-17 |
|
4 | AKAO |
Achaogen Inc
Series C Preferred Stock |
C - Conversion | -15,799 | 0 | -100.00 | ||||
2014-03-17 |
|
4 | AKAO |
Achaogen Inc
Series B Preferred Stock |
C - Conversion | -10,661 | 0 | -100.00 | ||||
2014-03-17 |
|
4 | AKAO |
Achaogen Inc
Series D Preferred Stock |
C - Conversion | -435,663 | 0 | -100.00 | ||||
2014-03-17 |
|
4 | AKAO |
Achaogen Inc
Series C Preferred Stock |
C - Conversion | -926,321 | 0 | -100.00 | ||||
2014-03-17 |
|
4 | AKAO |
Achaogen Inc
Series B Preferred Stock |
C - Conversion | -625,065 | 0 | -100.00 | ||||
2014-03-17 |
|
4 | AKAO |
Achaogen Inc
Common Stock |
C - Conversion | 33,890 | 33,890 | |||||
2014-03-17 |
|
4 | AKAO |
Achaogen Inc
Common Stock |
C - Conversion | 1,987,049 | 1,987,049 | |||||
2014-02-14 |
|
4 | CADX |
CADENCE PHARMACEUTICALS INC
Warrants to Purchase Common Stock |
M - Exercise | -1,367,020 | 0 | -100.00 | ||||
2014-02-14 |
|
4 | CADX |
CADENCE PHARMACEUTICALS INC
Common Stock |
F - Taxes | -765,532 | 2,972,678 | -20.48 | 14.00 | -10,717,448 | 41,617,492 | |
2014-02-14 |
|
4 | CADX |
CADENCE PHARMACEUTICALS INC
Common Stock |
M - Exercise | 1,367,020 | 3,738,210 | 57.65 | 7.84 | 10,717,437 | 29,307,566 | |
2014-02-14 |
|
4 | CADX |
CADENCE PHARMACEUTICALS INC
Warrants to Purchase Common Stock |
M - Exercise | -23,317 | 0 | -100.00 | ||||
2014-02-14 |
|
4 | CADX |
CADENCE PHARMACEUTICALS INC
Common Stock |
F - Taxes | -13,058 | 50,743 | -20.47 | 14.00 | -182,812 | 710,402 | |
2014-02-14 |
|
4 | CADX |
CADENCE PHARMACEUTICALS INC
Common Stock |
M - Exercise | 23,317 | 63,801 | 57.60 | 7.84 | 182,805 | 500,200 | |
2014-02-04 |
|
4 | DRNA |
Dicerna Pharmaceuticals Inc
Warrant |
C - Conversion | 156 | 156 | |||||
2014-02-04 |
|
4 | DRNA |
Dicerna Pharmaceuticals Inc
Warrant |
C - Conversion | -156 | 0 | -100.00 | ||||
2014-02-04 |
|
4 | DRNA |
Dicerna Pharmaceuticals Inc
Series C Preferred Stock |
C - Conversion | -9,469 | 0 | -100.00 | ||||
2014-02-04 |
|
4 | DRNA |
Dicerna Pharmaceuticals Inc
Series B Preferred Stock |
C - Conversion | -3,535 | 0 | -100.00 | ||||
2014-02-04 |
|
4 | DRNA |
Dicerna Pharmaceuticals Inc
Warrant |
C - Conversion | 21,041 | 21,041 | |||||
2014-02-04 |
|
4 | DRNA |
Dicerna Pharmaceuticals Inc
Warrant |
C - Conversion | -21,041 | 0 | -100.00 | ||||
2014-02-04 |
|
4 | DRNA |
Dicerna Pharmaceuticals Inc
Series C Preferred Stock |
C - Conversion | -1,276,243 | 0 | -100.00 | ||||
2014-02-04 |
|
4 | DRNA |
Dicerna Pharmaceuticals Inc
Series B Preferred Stock |
C - Conversion | -476,464 | 0 | -100.00 | ||||
2014-02-04 |
|
4 | DRNA |
Dicerna Pharmaceuticals Inc
Common Stock |
C - Conversion | 13,004 | 13,004 | |||||
2014-02-04 |
|
4 | DRNA |
Dicerna Pharmaceuticals Inc
Common Stock |
C - Conversion | 1,752,707 | 1,752,707 | |||||
2014-01-17 |
|
4 | ALIM |
ALIMERA SCIENCES INC
Common Stock |
S - Sale | X | -2,230 | 34,907 | -6.00 | 6.56 | -14,629 | 228,990 |
2014-01-17 |
|
4 | ALIM |
ALIMERA SCIENCES INC
Common Stock |
S - Sale | X | -1,010 | 37,137 | -2.65 | 6.01 | -6,070 | 223,193 |
2014-01-17 |
|
4 | ALIM |
ALIMERA SCIENCES INC
Common Stock |
S - Sale | X | -204,315 | 3,590,931 | -5.38 | 6.56 | -1,340,306 | 23,556,507 |
2014-01-17 |
|
4 | ALIM |
ALIMERA SCIENCES INC
Common Stock |
S - Sale | X | -92,445 | 3,795,246 | -2.38 | 6.01 | -555,594 | 22,809,428 |
2013-11-19 |
|
4 | TNDM |
TANDEM DIABETES CARE INC
Warrant to Purchase Common Stock |
J - Other | 6,008 | 6,008 | |||||
2013-11-19 |
|
4 | TNDM |
TANDEM DIABETES CARE INC
Warrant to Purchase Series D Preferred Stock |
J - Other | -10,068 | 0 | -100.00 | ||||
2013-11-19 |
|
4 | TNDM |
TANDEM DIABETES CARE INC
Series D Preferred Stock |
C - Conversion | -38,941 | 0 | -100.00 | ||||
2013-11-19 |
|
4 | TNDM |
TANDEM DIABETES CARE INC
Series C Preferred Stock |
C - Conversion | -9,378 | 0 | -100.00 | ||||
2013-11-19 |
|
4 | TNDM |
TANDEM DIABETES CARE INC
Series B Preferred Stock |
C - Conversion | -6,071 | 0 | -100.00 | ||||
2013-11-19 |
|
4 | TNDM |
TANDEM DIABETES CARE INC
Warrant to Purchase Common Stock |
J - Other | 352,351 | 352,351 | |||||
2013-11-19 |
|
4 | TNDM |
TANDEM DIABETES CARE INC
Warrant to Purchase Series D Preferred Stock |
J - Other | -590,403 | 0 | -100.00 | ||||
2013-11-19 |
|
4 | TNDM |
TANDEM DIABETES CARE INC
Series D Preferred Stock |
C - Conversion | -2,283,114 | 0 | -100.00 | ||||
2013-11-19 |
|
4 | TNDM |
TANDEM DIABETES CARE INC
Series C Preferred Stock |
C - Conversion | -549,833 | 0 | -100.00 | ||||
2013-11-19 |
|
4 | TNDM |
TANDEM DIABETES CARE INC
Series B Preferred Stock |
C - Conversion | -356,111 | 0 | -100.00 | ||||
2013-11-19 |
|
4 | TNDM |
TANDEM DIABETES CARE INC
Common Stock |
C - Conversion | 54,390 | 54,390 | |||||
2013-11-19 |
|
4 | TNDM |
TANDEM DIABETES CARE INC
Common Stock |
C - Conversion | 3,189,058 | 3,189,058 | |||||
2013-11-04 |
|
4 | VCYT |
VERACYTE, INC.
Series C Preferred Stock |
C - Conversion | -5,053 | 0 | -100.00 | ||||
2013-11-04 |
|
4 | VCYT |
VERACYTE, INC.
Series C Preferred Stock |
C - Conversion | -680,972 | 0 | -100.00 | ||||
2013-11-04 |
|
4 | VCYT |
VERACYTE, INC.
Series B Preferred Stock |
C - Conversion | -17,677 | 0 | -100.00 | ||||
2013-11-04 |
|
4 | VCYT |
VERACYTE, INC.
Series B Preferred Stock |
C - Conversion | -2,382,322 | 0 | -100.00 | ||||
2013-11-04 |
|
4 | VCYT |
VERACYTE, INC.
Common Stock |
C - Conversion | 22,730 | 22,730 | |||||
2013-11-04 |
|
4 | VCYT |
VERACYTE, INC.
Common Stock |
C - Conversion | 3,063,294 | 3,063,294 | |||||
2013-09-30 |
|
4 | EVOK |
Evoke Pharma Inc
Series A Preferred Stock |
C - Conversion | -19,006 | 0 | -100.00 | ||||
2013-09-30 |
|
4 | EVOK |
Evoke Pharma Inc
Series A Preferred Stock |
C - Conversion | -1,114,327 | 0 | -100.00 | ||||
2013-09-30 |
|
4 | EVOK |
Evoke Pharma Inc
Common Stock |
C - Conversion | 19,006 | 19,006 | |||||
2013-09-30 |
|
4 | EVOK |
Evoke Pharma Inc
Common Stock |
C - Conversion | 1,114,327 | 1,114,327 | |||||
2013-09-24 | 3 | EVOK |
Evoke Pharma Inc
Common Stock |
5,250 | ||||||||
2013-08-28 |
|
4 | RGDO |
Regado Biosciences Inc
Series D Preferred Stock |
C - Conversion | -7,407 | 0 | -100.00 | ||||
2013-08-28 |
|
4 | RGDO |
Regado Biosciences Inc
Series C Preferred Stock |
C - Conversion | -2,899 | 0 | -100.00 | ||||
2013-08-28 |
|
4 | RGDO |
Regado Biosciences Inc
Series B Preferred Stock |
C - Conversion | -4,233 | 0 | -100.00 | ||||
2013-08-28 |
|
4 | RGDO |
Regado Biosciences Inc
Series E Preferred Stock |
C - Conversion | -225,913 | 0 | -100.00 | ||||
2013-08-28 |
|
4 | RGDO |
Regado Biosciences Inc
Series D Preferred Stock |
C - Conversion | -894,120 | 0 | -100.00 | ||||
2013-08-28 |
|
4 | RGDO |
Regado Biosciences Inc
Series C Preferred Stock |
C - Conversion | -270,568 | 0 | -100.00 | ||||
2013-08-28 |
|
4 | RGDO |
Regado Biosciences Inc
Series B Preferred Stock |
C - Conversion | -394,969 | 0 | -100.00 | ||||
2013-08-28 |
|
4 | RGDO |
Regado Biosciences Inc
Common Stock |
C - Conversion | 7,407 | 14,920 | 98.59 | ||||
2013-08-28 |
|
4 | RGDO |
Regado Biosciences Inc
Common Stock |
C - Conversion | 2,899 | 7,513 | 62.83 | ||||
2013-08-28 |
|
4 | RGDO |
Regado Biosciences Inc
Common Stock |
C - Conversion | 4,233 | 4,614 | 1,111.02 | ||||
2013-08-28 |
|
4 | RGDO |
Regado Biosciences Inc
Common Stock |
P - Purchase | 750,000 | 2,571,117 | 41.18 | 4.00 | 3,000,000 | 10,284,468 | |
2013-08-28 |
|
4 | RGDO |
Regado Biosciences Inc
Common Stock |
C - Conversion | 225,913 | 1,821,117 | 14.16 | ||||
2013-08-28 |
|
4 | RGDO |
Regado Biosciences Inc
Common Stock |
C - Conversion | 894,120 | 1,595,204 | 127.53 | ||||
2013-08-28 |
|
4 | RGDO |
Regado Biosciences Inc
Common Stock |
C - Conversion | 270,568 | 701,084 | 62.85 | ||||
2013-08-28 |
|
4 | RGDO |
Regado Biosciences Inc
Common Stock |
C - Conversion | 394,969 | 430,516 | 1,111.12 | ||||
2013-08-21 | 3 | RGDO |
Regado Biosciences Inc
Common Stock |
35,547 | ||||||||
2013-08-21 | 3 | RGDO |
Regado Biosciences Inc
Common Stock |
381 | ||||||||
2013-08-21 | 3 | RGDO |
Regado Biosciences Inc
Common Stock |
17,171 | ||||||||
2013-07-31 |
|
4/A | OCRX |
Ocera Therapeutics, Inc.
Common Stock |
P - Purchase | 331,873 | 1,857,036 | 21.76 | 6.03 | 1,999,999 | 11,191,242 | |
2013-07-31 |
|
4/A | OCRX |
Ocera Therapeutics, Inc.
Common Stock |
P - Purchase | 7,333 | 7,333 | 6.03 | 44,192 | 44,192 | ||
2013-07-31 |
|
4/A | OCRX |
Ocera Therapeutics, Inc.
Common Stock |
P - Purchase | 988,285 | 988,285 | 6.03 | 5,955,801 | 5,955,801 | ||
2013-07-31 | 3/A | OCRX |
Ocera Therapeutics, Inc.
Common Stock |
47,963 | ||||||||
2013-07-31 | 3/A | OCRX |
Ocera Therapeutics, Inc.
Common Stock |
1,525,163 | ||||||||
2013-07-31 | 3/A | OCRX |
Ocera Therapeutics, Inc.
Common Stock |
15,731 | ||||||||
2013-07-16 |
|
4 | OCRX |
Ocera Therapeutics, Inc.
Common Stock |
P - Purchase | 331,873 | 1,897,336 | 21.20 | 6.03 | 1,999,999 | 11,434,106 | |
2013-07-16 |
|
4 | OCRX |
Ocera Therapeutics, Inc.
Common Stock |
P - Purchase | 7,333 | 7,333 | 6.03 | 44,192 | 44,192 | ||
2013-07-16 |
|
4 | OCRX |
Ocera Therapeutics, Inc.
Common Stock |
P - Purchase | 988,285 | 988,285 | 6.03 | 5,955,801 | 5,955,801 | ||
2013-07-16 | 3 | OCRX |
Ocera Therapeutics, Inc.
Common Stock |
47,963 | ||||||||
2013-07-16 | 3 | OCRX |
Ocera Therapeutics, Inc.
Common Stock |
1,565,463 | ||||||||
2013-07-16 | 3 | OCRX |
Ocera Therapeutics, Inc.
Common Stock |
15,731 | ||||||||
2013-07-02 |
|
4 | ESPR |
Esperion Therapeutics, Inc.
Warrant to Purchase Common Stock |
J - Other | 1,193 | 1,193 | |||||
2013-07-02 |
|
4 | ESPR |
Esperion Therapeutics, Inc.
Warrant to Purchase Series A Preferred Stock |
J - Other | -8,346 | 0 | -100.00 | ||||
2013-07-02 |
|
4 | ESPR |
Esperion Therapeutics, Inc.
Series A Preferred Stock |
C - Conversion | -30,462 | 0 | -100.00 | ||||
2013-07-02 |
|
4 | ESPR |
Esperion Therapeutics, Inc.
Warrant to Purchase Common Stock |
J - Other | 70,042 | 70,042 | |||||
2013-07-02 |
|
4 | ESPR |
Esperion Therapeutics, Inc.
Warrant to Purchase Series A Preferred Stock |
J - Other | -489,320 | 0 | -100.00 | ||||
2013-07-02 |
|
4 | ESPR |
Esperion Therapeutics, Inc.
Series A Preferred Stock |
C - Conversion | -1,786,012 | 0 | -100.00 | ||||
2013-07-02 |
|
4 | ESPR |
Esperion Therapeutics, Inc.
Common Stock |
P - Purchase | 4,791 | 35,253 | 15.73 | 14.00 | 67,074 | 493,542 | |
2013-07-02 |
|
4 | ESPR |
Esperion Therapeutics, Inc.
Common Stock |
C - Conversion | 30,462 | 30,462 | |||||
2013-07-02 |
|
4 | ESPR |
Esperion Therapeutics, Inc.
Common Stock |
P - Purchase | 280,923 | 2,066,935 | 15.73 | 14.00 | 3,932,922 | 28,937,090 | |
2013-07-02 |
|
4 | ESPR |
Esperion Therapeutics, Inc.
Common Stock |
C - Conversion | 1,786,012 | 1,786,012 | |||||
2013-06-25 | 3 | ESPR |
Esperion Therapeutics, Inc.
Common Stock |
21,471 | ||||||||
2013-06-24 |
|
4 | ALIM |
ALIMERA SCIENCES INC
Common Stock |
S - Sale | X | -114 | 38,147 | -0.30 | 5.01 | -571 | 191,116 |
2013-06-24 |
|
4 | ALIM |
ALIMERA SCIENCES INC
Common Stock |
S - Sale | X | -10,516 | 3,887,691 | -0.27 | 5.01 | -52,685 | 19,477,332 |
2013-06-20 |
|
4 | ALIM |
ALIMERA SCIENCES INC
Common Stock |
S - Sale | X | -22,423 | 3,898,207 | -0.57 | 5.37 | -120,412 | 20,933,372 |
2013-06-20 |
|
4 | ALIM |
ALIMERA SCIENCES INC
Common Stock |
S - Sale | X | -32,855 | 3,920,630 | -0.83 | 5.40 | -177,417 | 21,171,402 |
2013-06-20 |
|
4 | ALIM |
ALIMERA SCIENCES INC
Common Stock |
S - Sale | X | -244 | 38,261 | -0.63 | 5.37 | -1,310 | 205,462 |
2013-06-20 |
|
4 | ALIM |
ALIMERA SCIENCES INC
Common Stock |
S - Sale | X | -359 | 38,505 | -0.92 | 5.40 | -1,939 | 207,927 |
2013-06-19 |
|
4 | ZGNX |
ZOGENIX, INC.
Stock Option (Right to Buy) |
A - Award | 45,000 | 45,000 | |||||
2013-06-18 |
|
4 | ALIM |
ALIMERA SCIENCES INC
Common Stock |
S - Sale | X | -959 | 38,864 | -2.41 | 5.40 | -5,179 | 209,866 |
2013-06-18 |
|
4 | ALIM |
ALIMERA SCIENCES INC
Common Stock |
S - Sale | X | -425 | 39,823 | -1.06 | 5.03 | -2,138 | 200,310 |
2013-06-18 |
|
4 | ALIM |
ALIMERA SCIENCES INC
Common Stock |
S - Sale | X | -87,812 | 3,953,485 | -2.17 | 5.40 | -474,185 | 21,348,819 |
2013-06-18 |
|
4 | ALIM |
ALIMERA SCIENCES INC
Common Stock |
S - Sale | X | -38,897 | 4,041,297 | -0.95 | 5.03 | -195,652 | 20,327,724 |
2013-06-14 |
|
4 | CLVS |
Clovis Oncology, Inc.
Stock Option (Right to buy) |
A - Award | 12,414 | 12,414 | |||||
2013-06-13 |
|
4 | CADX |
CADENCE PHARMACEUTICALS INC
Stock Option (Right to buy) |
A - Award | 25,000 | 25,000 | |||||
2013-06-13 |
|
4 | ALIM |
ALIMERA SCIENCES INC
Common Stock |
S - Sale | X | -59 | 40,248 | -0.15 | 5.00 | -295 | 201,240 |
2013-06-13 |
|
4 | ALIM |
ALIMERA SCIENCES INC
Common Stock |
S - Sale | X | -5,337 | 4,080,194 | -0.13 | 5.00 | -26,685 | 20,400,970 |
2013-06-05 |
|
4 | CLVS |
Clovis Oncology, Inc.
Common Stock |
S - Sale | -159,192 | 2,581,745 | -5.81 | 64.58 | -10,280,619 | 166,729,092 | |
2013-06-05 |
|
4 | CLVS |
Clovis Oncology, Inc.
Common Stock |
S - Sale | -2,779 | 44,034 | -5.94 | 64.58 | -179,468 | 2,843,716 | |
2013-05-17 |
|
4 | ALIM |
ALIMERA SCIENCES INC
Common Stock |
S - Sale | -232 | 40,307 | -0.57 | 4.50 | -1,044 | 181,382 | |
2013-05-17 |
|
4 | ALIM |
ALIMERA SCIENCES INC
Common Stock |
S - Sale | -251 | 40,539 | -0.62 | 4.70 | -1,180 | 190,533 | |
2013-05-17 |
|
4 | ALIM |
ALIMERA SCIENCES INC
Common Stock |
S - Sale | -21,276 | 4,085,531 | -0.52 | 4.50 | -95,742 | 18,384,890 | |
2013-05-17 |
|
4 | ALIM |
ALIMERA SCIENCES INC
Common Stock |
S - Sale | -22,966 | 4,106,807 | -0.56 | 4.70 | -107,940 | 19,301,993 | |
2013-04-17 |
|
4 | CADX |
CADENCE PHARMACEUTICALS INC
Common Stock |
S - Sale | X | -23,210 | 2,371,190 | -0.97 | 6.62 | -153,650 | 15,697,278 |
2013-04-17 |
|
4 | CADX |
CADENCE PHARMACEUTICALS INC
Common Stock |
S - Sale | X | -71,578 | 7,313,241 | -0.97 | 6.62 | -473,846 | 48,413,655 |
2013-04-10 |
|
4 | CADX |
CADENCE PHARMACEUTICALS INC
Common Stock |
S - Sale | X | -1,567 | 2,394,400 | -0.07 | 6.72 | -10,530 | 16,090,368 |
2013-04-10 |
|
4 | CADX |
CADENCE PHARMACEUTICALS INC
Common Stock |
S - Sale | X | -11,386 | 2,395,967 | -0.47 | 6.71 | -76,400 | 16,076,939 |
2013-04-10 |
|
4 | CADX |
CADENCE PHARMACEUTICALS INC
Common Stock |
S - Sale | X | -12,217 | 2,407,353 | -0.50 | 6.52 | -79,655 | 15,695,942 |
2013-04-10 |
|
4 | CADX |
CADENCE PHARMACEUTICALS INC
Common Stock |
S - Sale | X | -4,832 | 7,384,819 | -0.07 | 6.72 | -32,471 | 49,625,984 |
2013-04-10 |
|
4 | CADX |
CADENCE PHARMACEUTICALS INC
Common Stock |
S - Sale | X | -35,114 | 7,389,651 | -0.47 | 6.71 | -235,615 | 49,584,558 |
2013-04-10 |
|
4 | CADX |
CADENCE PHARMACEUTICALS INC
Common Stock |
S - Sale | X | -37,676 | 7,424,765 | -0.50 | 6.52 | -245,648 | 48,409,468 |
2013-03-22 |
|
4 | CADX |
CADENCE PHARMACEUTICALS INC
Common Stock |
S - Sale | X | -4,374 | 2,419,570 | -0.18 | 5.35 | -23,401 | 12,944,700 |
2013-03-22 |
|
4 | CADX |
CADENCE PHARMACEUTICALS INC
Common Stock |
S - Sale | X | -893 | 40,484 | -2.16 | 5.49 | -4,903 | 222,257 |
2013-03-22 |
|
4 | CADX |
CADENCE PHARMACEUTICALS INC
Common Stock |
S - Sale | X | -13,490 | 7,462,441 | -0.18 | 5.35 | -72,172 | 39,924,059 |
2013-03-22 |
|
4 | CADX |
CADENCE PHARMACEUTICALS INC
Common Stock |
S - Sale | X | -1,743 | 78,369 | -2.18 | 5.49 | -9,569 | 430,246 |
2013-03-21 |
|
4 | CADX |
CADENCE PHARMACEUTICALS INC
Common Stock |
S - Sale | X | -5,510 | 2,423,944 | -0.23 | 5.22 | -28,762 | 12,652,988 |
2013-03-21 |
|
4 | CADX |
CADENCE PHARMACEUTICALS INC
Common Stock |
S - Sale | X | -7,925 | 2,429,454 | -0.33 | 5.19 | -41,131 | 12,608,866 |
2013-03-21 |
|
4 | CADX |
CADENCE PHARMACEUTICALS INC
Common Stock |
S - Sale | X | -92 | 41,377 | -0.22 | 5.22 | -480 | 215,988 |
2013-03-21 |
|
4 | CADX |
CADENCE PHARMACEUTICALS INC
Common Stock |
S - Sale | X | -134 | 41,469 | -0.32 | 5.19 | -695 | 215,224 |
2013-03-21 |
|
4 | CADX |
CADENCE PHARMACEUTICALS INC
Common Stock |
S - Sale | X | -182 | 80,112 | -0.23 | 5.22 | -950 | 418,185 |
2013-03-21 |
|
4 | CADX |
CADENCE PHARMACEUTICALS INC
Common Stock |
S - Sale | X | -261 | 80,294 | -0.32 | 5.19 | -1,355 | 416,726 |
2013-03-21 |
|
4 | CADX |
CADENCE PHARMACEUTICALS INC
Common Stock |
S - Sale | X | -16,995 | 7,475,931 | -0.23 | 5.22 | -88,714 | 39,024,360 |
2013-03-21 |
|
4 | CADX |
CADENCE PHARMACEUTICALS INC
Common Stock |
S - Sale | X | -24,442 | 7,492,926 | -0.33 | 5.19 | -126,854 | 38,888,286 |
2013-03-19 |
|
4 | CADX |
CADENCE PHARMACEUTICALS INC
Common Stock |
S - Sale | X | -8,020 | 2,437,379 | -0.33 | 5.16 | -41,383 | 12,576,876 |
2013-03-19 |
|
4 | CADX |
CADENCE PHARMACEUTICALS INC
Common Stock |
S - Sale | X | -9,636 | 2,445,399 | -0.39 | 5.28 | -50,878 | 12,911,707 |
2013-03-19 |
|
4 | CADX |
CADENCE PHARMACEUTICALS INC
Common Stock |
S - Sale | X | -135 | 41,603 | -0.32 | 5.16 | -697 | 214,671 |
2013-03-19 |
|
4 | CADX |
CADENCE PHARMACEUTICALS INC
Common Stock |
S - Sale | X | -163 | 41,738 | -0.39 | 5.28 | -861 | 220,377 |
2013-03-19 |
|
4 | CADX |
CADENCE PHARMACEUTICALS INC
Common Stock |
S - Sale | X | -265 | 80,555 | -0.33 | 5.16 | -1,367 | 415,664 |
2013-03-19 |
|
4 | CADX |
CADENCE PHARMACEUTICALS INC
Common Stock |
S - Sale | X | -318 | 80,820 | -0.39 | 5.28 | -1,679 | 426,730 |
2013-03-19 |
|
4 | CADX |
CADENCE PHARMACEUTICALS INC
Common Stock |
S - Sale | X | -24,736 | 7,517,368 | -0.33 | 5.16 | -127,638 | 38,789,619 |
2013-03-19 |
|
4 | CADX |
CADENCE PHARMACEUTICALS INC
Common Stock |
S - Sale | X | -29,719 | 7,542,104 | -0.39 | 5.28 | -156,916 | 39,822,309 |
2013-03-15 |
|
4 | CADX |
CADENCE PHARMACEUTICALS INC
Common Stock |
S - Sale | X | -5,020 | 2,455,035 | -0.20 | 5.36 | -26,907 | 13,158,988 |
2013-03-15 |
|
4 | CADX |
CADENCE PHARMACEUTICALS INC
Common Stock |
S - Sale | X | -7,733 | 2,460,055 | -0.31 | 5.40 | -41,758 | 13,284,297 |
2013-03-15 |
|
4 | CADX |
CADENCE PHARMACEUTICALS INC
Common Stock |
S - Sale | X | -85 | 41,901 | -0.20 | 5.36 | -456 | 224,589 |
2013-03-15 |
|
4 | CADX |
CADENCE PHARMACEUTICALS INC
Common Stock |
S - Sale | X | -131 | 41,986 | -0.31 | 5.40 | -707 | 226,724 |
2013-03-15 |
|
4 | CADX |
CADENCE PHARMACEUTICALS INC
Common Stock |
S - Sale | X | -166 | 81,138 | -0.20 | 5.36 | -890 | 434,900 |
2013-03-15 |
|
4 | CADX |
CADENCE PHARMACEUTICALS INC
Common Stock |
S - Sale | X | -256 | 81,304 | -0.31 | 5.40 | -1,382 | 439,042 |
2013-03-15 |
|
4 | CADX |
CADENCE PHARMACEUTICALS INC
Common Stock |
S - Sale | X | -15,480 | 7,571,823 | -0.20 | 5.36 | -82,973 | 40,584,971 |
2013-03-15 |
|
4 | CADX |
CADENCE PHARMACEUTICALS INC
Common Stock |
S - Sale | X | -23,848 | 7,587,303 | -0.31 | 5.40 | -128,779 | 40,971,436 |
2013-03-13 |
|
4 | CADX |
CADENCE PHARMACEUTICALS INC
Common Stock |
S - Sale | X | -6,346 | 2,467,788 | -0.26 | 5.38 | -34,141 | 13,276,699 |
2013-03-13 |
|
4 | CADX |
CADENCE PHARMACEUTICALS INC
Common Stock |
S - Sale | X | -4,118 | 2,474,134 | -0.17 | 5.34 | -21,990 | 13,211,876 |
2013-03-13 |
|
4 | CADX |
CADENCE PHARMACEUTICALS INC
Common Stock |
S - Sale | X | -107 | 42,117 | -0.25 | 5.38 | -576 | 226,589 |
2013-03-13 |
|
4 | CADX |
CADENCE PHARMACEUTICALS INC
Common Stock |
S - Sale | X | -70 | 42,224 | -0.17 | 5.34 | -374 | 225,476 |
2013-03-13 |
|
4 | CADX |
CADENCE PHARMACEUTICALS INC
Common Stock |
S - Sale | X | -210 | 81,560 | -0.26 | 5.38 | -1,130 | 438,793 |
2013-03-13 |
|
4 | CADX |
CADENCE PHARMACEUTICALS INC
Common Stock |
S - Sale | X | -136 | 81,770 | -0.17 | 5.34 | -726 | 436,652 |
2013-03-13 |
|
4 | CADX |
CADENCE PHARMACEUTICALS INC
Common Stock |
S - Sale | X | -19,569 | 7,611,151 | -0.26 | 5.38 | -105,281 | 40,947,992 |
2013-03-13 |
|
4 | CADX |
CADENCE PHARMACEUTICALS INC
Common Stock |
S - Sale | X | -12,700 | 7,630,720 | -0.17 | 5.34 | -67,818 | 40,748,045 |
2013-03-11 |
|
4 | CADX |
CADENCE PHARMACEUTICALS INC
Common Stock |
S - Sale | X | -5,154 | 2,478,252 | -0.21 | 5.32 | -27,419 | 13,184,301 |
2013-03-11 |
|
4 | CADX |
CADENCE PHARMACEUTICALS INC
Common Stock |
S - Sale | X | -12,701 | 2,483,406 | -0.51 | 5.22 | -66,299 | 12,963,379 |
2013-03-11 |
|
4 | CADX |
CADENCE PHARMACEUTICALS INC
Common Stock |
S - Sale | X | -88 | 42,294 | -0.21 | 5.32 | -468 | 225,004 |
2013-03-11 |
|
4 | CADX |
CADENCE PHARMACEUTICALS INC
Common Stock |
S - Sale | X | -215 | 42,382 | -0.50 | 5.22 | -1,122 | 221,234 |
2013-03-11 |
|
4 | CADX |
CADENCE PHARMACEUTICALS INC
Common Stock |
S - Sale | X | -171 | 81,906 | -0.21 | 5.32 | -910 | 435,740 |
2013-03-11 |
|
4 | CADX |
CADENCE PHARMACEUTICALS INC
Common Stock |
S - Sale | X | -420 | 82,077 | -0.51 | 5.22 | -2,192 | 428,442 |
2013-03-11 |
|
4 | CADX |
CADENCE PHARMACEUTICALS INC
Common Stock |
S - Sale | X | -15,892 | 7,643,420 | -0.21 | 5.32 | -84,545 | 40,662,994 |
2013-03-11 |
|
4 | CADX |
CADENCE PHARMACEUTICALS INC
Common Stock |
S - Sale | X | -39,168 | 7,659,312 | -0.51 | 5.22 | -204,457 | 39,981,609 |
2013-03-07 |
|
4 | CADX |
CADENCE PHARMACEUTICALS INC
Common Stock |
S - Sale | X | -3,839 | 2,496,107 | -0.15 | 5.06 | -19,425 | 12,630,301 |
2013-03-07 |
|
4 | CADX |
CADENCE PHARMACEUTICALS INC
Common Stock |
S - Sale | X | -4,039 | 2,499,946 | -0.16 | 5.01 | -20,235 | 12,524,729 |
2013-03-07 |
|
4 | CADX |
CADENCE PHARMACEUTICALS INC
Common Stock |
S - Sale | X | -65 | 42,597 | -0.15 | 5.06 | -329 | 215,541 |
2013-03-07 |
|
4 | CADX |
CADENCE PHARMACEUTICALS INC
Common Stock |
S - Sale | X | -69 | 42,662 | -0.16 | 5.01 | -346 | 213,737 |
2013-03-07 |
|
4 | CADX |
CADENCE PHARMACEUTICALS INC
Common Stock |
S - Sale | X | -11,841 | 7,698,480 | -0.15 | 5.06 | -59,915 | 38,954,309 |
2013-03-07 |
|
4 | CADX |
CADENCE PHARMACEUTICALS INC
Common Stock |
S - Sale | X | -12,454 | 7,710,321 | -0.16 | 5.01 | -62,395 | 38,628,708 |
2013-03-07 |
|
4 | CADX |
CADENCE PHARMACEUTICALS INC
Common Stock |
S - Sale | X | -127 | 82,497 | -0.15 | 5.06 | -643 | 417,435 |
2013-03-07 |
|
4 | CADX |
CADENCE PHARMACEUTICALS INC
Common Stock |
S - Sale | X | -134 | 82,624 | -0.16 | 5.01 | -671 | 413,946 |
2013-03-06 |
|
4 | CLVS |
Clovis Oncology, Inc.
Common Stock |
S - Sale | -1,651 | 46,813 | -3.41 | 24.51 | -40,466 | 1,147,387 | |
2013-03-06 |
|
4 | CLVS |
Clovis Oncology, Inc.
Common Stock |
S - Sale | -2,132 | 48,464 | -4.21 | 24.69 | -52,639 | 1,196,576 | |
2013-03-06 |
|
4 | CLVS |
Clovis Oncology, Inc.
Common Stock |
S - Sale | -417 | 50,596 | -0.82 | 24.44 | -10,191 | 1,236,566 | |
2013-03-06 |
|
4 | CLVS |
Clovis Oncology, Inc.
Common Stock |
S - Sale | -98,349 | 2,740,937 | -3.46 | 24.51 | -2,410,534 | 67,180,366 | |
2013-03-06 |
|
4 | CLVS |
Clovis Oncology, Inc.
Common Stock |
S - Sale | -126,868 | 2,839,286 | -4.28 | 24.69 | -3,132,371 | 70,101,971 | |
2013-03-06 |
|
4 | CLVS |
Clovis Oncology, Inc.
Common Stock |
S - Sale | -24,783 | 2,966,154 | -0.83 | 24.44 | -605,697 | 72,492,804 | |
2013-03-05 |
|
4 | CADX |
CADENCE PHARMACEUTICALS INC
Common Stock |
S - Sale | X | -5,145 | 2,503,985 | -0.21 | 5.01 | -25,776 | 12,544,965 |
2013-03-05 |
|
4 | CADX |
CADENCE PHARMACEUTICALS INC
Common Stock |
S - Sale | X | -7,635 | 2,509,130 | -0.30 | 5.01 | -38,251 | 12,570,741 |
2013-03-05 |
|
4 | CADX |
CADENCE PHARMACEUTICALS INC
Common Stock |
S - Sale | X | -88 | 42,731 | -0.21 | 5.01 | -441 | 214,082 |
2013-03-05 |
|
4 | CADX |
CADENCE PHARMACEUTICALS INC
Common Stock |
S - Sale | X | -130 | 42,819 | -0.30 | 5.01 | -651 | 214,523 |
2013-03-05 |
|
4 | CADX |
CADENCE PHARMACEUTICALS INC
Common Stock |
S - Sale | X | -170 | 82,758 | -0.20 | 5.01 | -852 | 414,618 |
2013-03-05 |
|
4 | CADX |
CADENCE PHARMACEUTICALS INC
Common Stock |
S - Sale | X | -253 | 82,928 | -0.30 | 5.01 | -1,268 | 415,469 |
2013-03-05 |
|
4 | CADX |
CADENCE PHARMACEUTICALS INC
Common Stock |
S - Sale | X | -15,865 | 7,722,775 | -0.21 | 5.01 | -79,484 | 38,691,103 |
2013-03-05 |
|
4 | CADX |
CADENCE PHARMACEUTICALS INC
Common Stock |
S - Sale | X | -23,548 | 7,738,640 | -0.30 | 5.01 | -117,975 | 38,770,586 |
2013-02-22 |
|
4 | CADX |
CADENCE PHARMACEUTICALS INC
Common Stock |
S - Sale | X | -1,998 | 2,516,765 | -0.08 | 5.01 | -10,010 | 12,608,993 |
2013-02-22 |
|
4 | CADX |
CADENCE PHARMACEUTICALS INC
Common Stock |
S - Sale | X | -34 | 42,949 | -0.08 | 5.01 | -170 | 215,174 |
2013-02-22 |
|
4 | CADX |
CADENCE PHARMACEUTICALS INC
Common Stock |
S - Sale | X | -6,160 | 7,762,188 | -0.08 | 5.01 | -30,862 | 38,888,562 |
2013-02-22 |
|
4 | CADX |
CADENCE PHARMACEUTICALS INC
Common Stock |
S - Sale | X | -66 | 83,181 | -0.08 | 5.01 | -331 | 416,737 |
2013-02-20 |
|
4 | CADX |
CADENCE PHARMACEUTICALS INC
Common Stock |
S - Sale | X | -10,076 | 2,518,763 | -0.40 | 5.02 | -50,582 | 12,644,190 |
2013-02-20 |
|
4 | CADX |
CADENCE PHARMACEUTICALS INC
Common Stock |
S - Sale | X | -2,967 | 2,528,839 | -0.12 | 5.00 | -14,835 | 12,644,195 |
2013-02-20 |
|
4 | CADX |
CADENCE PHARMACEUTICALS INC
Common Stock |
S - Sale | X | -171 | 42,983 | -0.40 | 5.02 | -858 | 215,775 |
2013-02-20 |
|
4 | CADX |
CADENCE PHARMACEUTICALS INC
Common Stock |
S - Sale | X | -51 | 43,154 | -0.12 | 5.00 | -255 | 215,770 |
2013-02-20 |
|
4 | CADX |
CADENCE PHARMACEUTICALS INC
Common Stock |
S - Sale | X | -334 | 83,247 | -0.40 | 5.02 | -1,677 | 417,900 |
2013-02-20 |
|
4 | CADX |
CADENCE PHARMACEUTICALS INC
Common Stock |
S - Sale | X | -99 | 83,581 | -0.12 | 5.00 | -495 | 417,905 |
2013-02-20 |
|
4 | CADX |
CADENCE PHARMACEUTICALS INC
Common Stock |
S - Sale | X | -31,075 | 7,768,348 | -0.40 | 5.02 | -155,996 | 38,997,107 |
2013-02-20 |
|
4 | CADX |
CADENCE PHARMACEUTICALS INC
Common Stock |
S - Sale | X | -9,148 | 7,799,423 | -0.12 | 5.00 | -45,740 | 38,997,115 |
2013-02-15 |
|
4 | CADX |
CADENCE PHARMACEUTICALS INC
Common Stock |
S - Sale | X | -2,951 | 2,531,806 | -0.12 | 5.01 | -14,785 | 12,684,348 |
2013-02-15 |
|
4 | CADX |
CADENCE PHARMACEUTICALS INC
Common Stock |
S - Sale | X | -5,763 | 2,534,757 | -0.23 | 5.00 | -28,815 | 12,673,785 |
2013-02-15 |
|
4 | CADX |
CADENCE PHARMACEUTICALS INC
Common Stock |
S - Sale | X | -51 | 43,205 | -0.12 | 5.01 | -256 | 216,457 |
2013-02-15 |
|
4 | CADX |
CADENCE PHARMACEUTICALS INC
Common Stock |
S - Sale | X | -98 | 43,256 | -0.23 | 5.00 | -490 | 216,280 |
2013-02-15 |
|
4 | CADX |
CADENCE PHARMACEUTICALS INC
Common Stock |
S - Sale | X | -98 | 83,680 | -0.12 | 5.01 | -491 | 419,237 |
2013-02-15 |
|
4 | CADX |
CADENCE PHARMACEUTICALS INC
Common Stock |
S - Sale | X | -191 | 83,778 | -0.23 | 5.00 | -955 | 418,890 |
2013-02-15 |
|
4 | CADX |
CADENCE PHARMACEUTICALS INC
Common Stock |
S - Sale | X | -9,100 | 7,808,571 | -0.12 | 5.01 | -45,591 | 39,120,941 |
2013-02-15 |
|
4 | CADX |
CADENCE PHARMACEUTICALS INC
Common Stock |
S - Sale | X | -17,770 | 7,817,671 | -0.23 | 5.00 | -88,850 | 39,088,355 |
2013-02-05 |
|
4 | CADX |
CADENCE PHARMACEUTICALS INC
Common Stock |
S - Sale | X | -9,769 | 2,540,520 | -0.38 | 4.85 | -47,380 | 12,321,522 |
2013-02-05 |
|
4 | CADX |
CADENCE PHARMACEUTICALS INC
Common Stock |
S - Sale | X | -164 | 43,354 | -0.38 | 4.85 | -795 | 210,267 |
2013-02-05 |
|
4 | CADX |
CADENCE PHARMACEUTICALS INC
Common Stock |
S - Sale | X | -30,134 | 7,835,441 | -0.38 | 4.85 | -146,150 | 38,001,889 |
2013-02-05 |
|
4 | CADX |
CADENCE PHARMACEUTICALS INC
Common Stock |
S - Sale | X | -322 | 83,969 | -0.38 | 4.85 | -1,562 | 407,250 |
2013-02-01 |
|
4 | CADX |
CADENCE PHARMACEUTICALS INC
Common Stock |
S - Sale | X | -18,537 | 2,550,289 | -0.72 | 4.71 | -87,309 | 12,011,861 |
2013-02-01 |
|
4 | CADX |
CADENCE PHARMACEUTICALS INC
Common Stock |
S - Sale | X | -11,105 | 2,568,826 | -0.43 | 5.00 | -55,525 | 12,844,130 |
2013-02-01 |
|
4 | CADX |
CADENCE PHARMACEUTICALS INC
Common Stock |
S - Sale | X | -314 | 43,518 | -0.72 | 4.71 | -1,479 | 204,970 |
2013-02-01 |
|
4 | CADX |
CADENCE PHARMACEUTICALS INC
Common Stock |
S - Sale | X | -188 | 43,832 | -0.43 | 5.00 | -940 | 219,160 |
2013-02-01 |
|
4 | CADX |
CADENCE PHARMACEUTICALS INC
Common Stock |
S - Sale | X | -57,165 | 7,865,575 | -0.72 | 4.71 | -269,247 | 37,046,858 |
2013-02-01 |
|
4 | CADX |
CADENCE PHARMACEUTICALS INC
Common Stock |
S - Sale | X | -34,248 | 7,922,740 | -0.43 | 5.00 | -171,240 | 39,613,700 |
2013-02-01 |
|
4 | CADX |
CADENCE PHARMACEUTICALS INC
Common Stock |
S - Sale | X | -613 | 84,291 | -0.72 | 4.71 | -2,887 | 397,011 |
2013-02-01 |
|
4 | CADX |
CADENCE PHARMACEUTICALS INC
Common Stock |
S - Sale | X | -367 | 84,904 | -0.43 | 5.00 | -1,835 | 424,520 |
2013-01-30 |
|
4 | CADX |
CADENCE PHARMACEUTICALS INC
Common Stock |
S - Sale | X | -15,320 | 2,579,931 | -0.59 | 5.27 | -80,736 | 13,596,236 |
2013-01-30 |
|
4 | CADX |
CADENCE PHARMACEUTICALS INC
Common Stock |
S - Sale | X | -16,660 | 2,595,251 | -0.64 | 5.40 | -89,964 | 14,014,355 |
2013-01-30 |
|
4 | CADX |
CADENCE PHARMACEUTICALS INC
Common Stock |
S - Sale | X | -260 | 44,020 | -0.59 | 5.27 | -1,370 | 231,985 |
2013-01-30 |
|
4 | CADX |
CADENCE PHARMACEUTICALS INC
Common Stock |
S - Sale | X | -282 | 44,280 | -0.63 | 5.40 | -1,523 | 239,112 |
2013-01-30 |
|
4 | CADX |
CADENCE PHARMACEUTICALS INC
Common Stock |
S - Sale | X | -47,247 | 7,956,988 | -0.59 | 5.27 | -248,992 | 41,933,327 |
2013-01-30 |
|
4 | CADX |
CADENCE PHARMACEUTICALS INC
Common Stock |
S - Sale | X | -51,377 | 8,004,235 | -0.64 | 5.40 | -277,436 | 43,222,869 |
2013-01-30 |
|
4 | CADX |
CADENCE PHARMACEUTICALS INC
Common Stock |
S - Sale | X | -507 | 85,271 | -0.59 | 5.27 | -2,672 | 449,378 |
2013-01-30 |
|
4 | CADX |
CADENCE PHARMACEUTICALS INC
Common Stock |
S - Sale | X | -551 | 85,778 | -0.64 | 5.40 | -2,975 | 463,201 |
2013-01-28 |
|
4 | CADX |
CADENCE PHARMACEUTICALS INC
Common Stock |
S - Sale | X | -13,790 | 2,611,911 | -0.53 | 5.38 | -74,190 | 14,052,081 |
2013-01-28 |
|
4 | CADX |
CADENCE PHARMACEUTICALS INC
Common Stock |
S - Sale | X | -36,324 | 2,625,701 | -1.36 | 5.45 | -197,966 | 14,310,070 |
2013-01-28 |
|
4 | CADX |
CADENCE PHARMACEUTICALS INC
Common Stock |
S - Sale | X | -234 | 44,562 | -0.52 | 5.38 | -1,259 | 239,744 |
2013-01-28 |
|
4 | CADX |
CADENCE PHARMACEUTICALS INC
Common Stock |
S - Sale | X | -616 | 44,796 | -1.36 | 5.45 | -3,357 | 244,138 |
2013-01-28 |
|
4 | CADX |
CADENCE PHARMACEUTICALS INC
Common Stock |
S - Sale | X | -456 | 86,329 | -0.53 | 5.38 | -2,453 | 464,450 |
2013-01-28 |
|
4 | CADX |
CADENCE PHARMACEUTICALS INC
Common Stock |
S - Sale | X | -1,201 | 86,785 | -1.36 | 5.45 | -6,545 | 472,978 |
2013-01-28 |
|
4 | CADX |
CADENCE PHARMACEUTICALS INC
Common Stock |
S - Sale | X | -42,525 | 8,055,612 | -0.53 | 5.38 | -228,784 | 43,339,193 |
2013-01-28 |
|
4 | CADX |
CADENCE PHARMACEUTICALS INC
Common Stock |
S - Sale | X | -111,022 | 8,098,137 | -1.35 | 5.45 | -605,070 | 44,134,847 |
2013-01-24 |
|
4 | CADX |
CADENCE PHARMACEUTICALS INC
Common Stock |
S - Sale | X | -25,354 | 2,662,025 | -0.94 | 5.11 | -129,559 | 13,602,948 |
2013-01-24 |
|
4 | CADX |
CADENCE PHARMACEUTICALS INC
Common Stock |
S - Sale | X | -14,966 | 2,687,379 | -0.55 | 5.02 | -75,129 | 13,490,643 |
2013-01-24 |
|
4 | CADX |
CADENCE PHARMACEUTICALS INC
Common Stock |
S - Sale | X | -430 | 45,412 | -0.94 | 5.11 | -2,197 | 232,055 |
2013-01-24 |
|
4 | CADX |
CADENCE PHARMACEUTICALS INC
Common Stock |
S - Sale | X | -254 | 45,842 | -0.55 | 5.02 | -1,275 | 230,127 |
2013-01-24 |
|
4 | CADX |
CADENCE PHARMACEUTICALS INC
Common Stock |
S - Sale | X | -839 | 87,986 | -0.94 | 5.11 | -4,287 | 449,608 |
2013-01-24 |
|
4 | CADX |
CADENCE PHARMACEUTICALS INC
Common Stock |
S - Sale | X | -495 | 88,825 | -0.55 | 5.02 | -2,485 | 445,902 |
2013-01-24 |
|
4 | CADX |
CADENCE PHARMACEUTICALS INC
Common Stock |
S - Sale | X | -78,188 | 8,210,159 | -0.94 | 5.11 | -399,541 | 41,953,912 |
2013-01-24 |
|
4 | CADX |
CADENCE PHARMACEUTICALS INC
Common Stock |
S - Sale | X | -46,153 | 8,288,347 | -0.55 | 5.02 | -231,688 | 41,607,502 |
2013-01-22 |
|
4 | CADX |
CADENCE PHARMACEUTICALS INC
Common Stock |
S - Sale | X | -19,080 | 2,702,345 | -0.70 | 5.19 | -99,025 | 14,025,171 |
2013-01-22 |
|
4 | CADX |
CADENCE PHARMACEUTICALS INC
Common Stock |
S - Sale | X | -12,615 | 2,721,425 | -0.46 | 5.35 | -67,490 | 14,559,624 |
2013-01-22 |
|
4 | CADX |
CADENCE PHARMACEUTICALS INC
Common Stock |
S - Sale | X | -324 | 46,096 | -0.70 | 5.19 | -1,682 | 239,238 |
2013-01-22 |
|
4 | CADX |
CADENCE PHARMACEUTICALS INC
Common Stock |
S - Sale | X | -214 | 46,420 | -0.46 | 5.35 | -1,145 | 248,347 |
2013-01-22 |
|
4 | CADX |
CADENCE PHARMACEUTICALS INC
Common Stock |
S - Sale | X | -58,838 | 8,334,500 | -0.70 | 5.19 | -305,369 | 43,256,055 |
2013-01-22 |
|
4 | CADX |
CADENCE PHARMACEUTICALS INC
Common Stock |
S - Sale | X | -38,903 | 8,393,338 | -0.46 | 5.35 | -208,131 | 44,904,358 |
2013-01-22 |
|
4 | CADX |
CADENCE PHARMACEUTICALS INC
Common Stock |
S - Sale | X | -631 | 89,320 | -0.70 | 5.19 | -3,275 | 463,571 |
2013-01-22 |
|
4 | CADX |
CADENCE PHARMACEUTICALS INC
Common Stock |
S - Sale | X | -418 | 89,951 | -0.46 | 5.35 | -2,236 | 481,238 |
2013-01-18 |
|
4 | ACHN |
ACHILLION PHARMACEUTICALS INC
Common Stock |
J - Other | 66,462 | 159,896 | 71.13 | ||||
2013-01-18 |
|
4 | ACHN |
ACHILLION PHARMACEUTICALS INC
Common Stock |
J - Other | -1,000,000 | 5,772,968 | -14.76 | ||||
2013-01-15 | 3 | NONE |
Celator Pharmaceuticals Inc
Common Stock |
2,222,175 | ||||||||
2013-01-15 | 3 | NONE |
Celator Pharmaceuticals Inc
Common Stock |
16,733 | ||||||||
2013-01-15 | 3 | NONE |
Celator Pharmaceuticals Inc
Common Stock |
5,868 | ||||||||
2012-07-24 |
|
4 | DRTX |
Durata Therapeutics, Inc.
Series A Preferred Stock |
C - Conversion | -16,529 | 0 | -100.00 | ||||
2012-07-24 |
|
4 | DRTX |
Durata Therapeutics, Inc.
Series A Preferred Stock |
C - Conversion | -2,227,596 | 0 | -100.00 | ||||
2012-07-24 |
|
4 | DRTX |
Durata Therapeutics, Inc.
Common Stock |
P - Purchase | 5,777 | 22,306 | 34.95 | 9.00 | 51,993 | 200,754 | |
2012-07-24 |
|
4 | DRTX |
Durata Therapeutics, Inc.
Common Stock |
C - Conversion | 16,529 | 16,529 | |||||
2012-07-24 |
|
4 | DRTX |
Durata Therapeutics, Inc.
Common Stock |
P - Purchase | 778,536 | 3,006,132 | 34.95 | 9.00 | 7,006,824 | 27,055,188 | |
2012-07-24 |
|
4 | DRTX |
Durata Therapeutics, Inc.
Common Stock |
C - Conversion | 2,227,596 | 2,227,596 | |||||
2012-07-18 | 3 | DRTX |
Durata Therapeutics, Inc.
Common Stock |
6,250 | ||||||||
2012-06-18 |
|
4 | CLVS |
Clovis Oncology, Inc.
Stock Option (Right to buy) |
A - Award | 12,414 | 12,414 | |||||
2012-06-14 |
|
4 | CADX |
CADENCE PHARMACEUTICALS INC
Stock Option (Right to buy) |
A - Award | 17,500 | 17,500 | |||||
2012-06-08 |
|
4 | ZGNX |
ZOGENIX, INC.
Stock Option (Right to Buy) |
A - Award | 35,000 | 35,000 | |||||
2012-06-04 |
|
4 | ACHN |
ACHILLION PHARMACEUTICALS INC
Common Stock |
J - Other | 93,434 | 93,434 | |||||
2012-06-04 |
|
4 | ACHN |
ACHILLION PHARMACEUTICALS INC
Common Stock |
J - Other | -1,200,000 | 6,772,968 | -15.05 | ||||
2012-05-01 |
|
4 | ZGNX |
ZOGENIX, INC.
Stock Option (Right to Buy) |
A - Award | 50,000 | 50,000 | |||||
2012-03-27 |
|
4 | RVA |
REVA Medical, Inc.
Common Stock |
S - Sale | -39,136 | 85,186 | -31.48 | 5.16 | -201,942 | 439,560 | |
2012-03-27 |
|
4 | RVA |
REVA Medical, Inc.
Common Stock |
S - Sale | -1,656,581 | 3,606,002 | -31.48 | 5.16 | -8,547,958 | 18,606,970 | |
2007-05-09 |
|
4 | NUVA |
NUVASIVE INC
Common Stock |
J - Other | 3,457 | 3,457 | |||||
2007-05-09 |
|
4 | NUVA |
NUVASIVE INC
Common Stock |
J - Other | -17,740 | 0 | -100.00 | ||||
2005-05-04 |
|
4 | NUVA |
NUVASIVE INC
Common Stock |
J - Other | 5,840 | 5,840 | |||||
2005-05-04 |
|
4 | NUVA |
NUVASIVE INC
Common Stock |
J - Other | -584,000 | 1,168,455 | -33.32 |